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SUMMARY 
 
Prostate cancer (PCa) is the second most frequent malignancy in men worldwide and a 
common cause of cancer-related morbidity and mortality, constituting a major public health 
problem. Due to the multifocal and heterogeneous nature of this disease, it has become quite 
difficult to study its progression and define the most effective prevention strategies or 
treatment modalities. The lack of accurate methods able to differentiate between clinically 
insignificant and aggressive carcinomas has reinforced the need to better understand the 
underlying molecular genetic alterations and pathways behind prostate cancer initiation and 
tumorigenesis. 
One of the greatest discoveries in the field of prostate cancer was the identification of 
genomic rearrangements responsible for the formation of gene fusions involving the ETS 
family of transcription factors. The TMPRSS2-ERG is the most frequent type of chromosomal 
rearrangement present in nearly half of all human prostate cancers, followed by the ETV1, 
ETV4, ETV5 and FLI1 genes commonly fused with additional 5’ partners. These findings, 
considered to be early molecular events, are truly remarkable and represent a paradigmatic 
shift in the understanding of prostate carcinoma pathogenesis.  
Emerging studies addressing questions of redundant and specific carcinogenic roles 
have underscored the function of individual ETS family members in cell line models, namely 
the involvement of ERG, ETV1 and ETV5 in prostate invasive growth. In spite of this, the 
molecular mechanisms of other rarer ETS rearrangements are still unclear mostly due to the 
scarcity of prostate cancer cell lines with gene fusions suitable to be studied. Thus, the main 
aim of this thesis was to explore the mechanism and functional role of ETV4 overexpression 
in different cell line models with and without known genomic rearrangements in other ETS 
genes. 
To achieve this goal, an ETS quantitative expression analysis strategy was initially 
performed in five cell lines representing the diverse molecular subtypes of prostate cancer. 
We found ERG and ETV1 overexpression in VCaP and LNCaP cells, respectively, as well as 
ETV4 overexpression in PC-3 prostate cells. Interestingly, the MDA-PCa-2b cellular model 
showed co-overexpression of ETV1 and ETV4. A FISH approach was used to evaluate the 
presence of any chromosomal rearrangement involving the ETV4 locus in the PC-3 and 
MDA-PCa-2b cell lines. The former was shown to harbor an atypical genetic rearrangement 
around ETV4, whereas the latter was demonstrated to have a balanced translocation leading 
to the MIPOL1-ETV1 fusion and no mechanistically distinct rearrangement mediating the 
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aberrant overexpression of ETV4. Furthermore, the biological processes associated with 
ETV4 expression in PC-3 and MDA-PCa-2b prostate epithelial cells were also investigated. 
By shRNA technology, we showed that ETV4 inhibition in PC-3 derived cells significantly 
reduces not only cell anchorage-independent growth, but also cell invasion. The MDA-PCa-
2b ETV4-silenced cells also exhibited a decrease in the ability to grow in an anchorage-
independent way, but were barely able to invade in a Matrigel assay. 
 In order to identify and characterize potential downstream targets linked to ETV4 
activation in prostate cancer, a microarray analysis was used to assess whole-transcriptome 
expression levels associated with ETV4 silencing. Although gene expression results 
highlighted some novel or unexplored genes, the majority are annotated to play a role in cell 
cycle or cell growth. We found two (C1orf129; PAK1IP1) and six (FTH1; KIAA1199; PLK2; 
SPTLC3; TLL1; TMEM154) candidate genes up- and down-regulated, respectively, by ETV4 
in all the cell lines analyzed. 
Taken together, the data combining phenotype analyses after ETV4 silencing and 
whole-genome expression profiles revealed that ETV4 overexpression contributes to the 
neoplastic process and transformation program of prostate cancer cells. This work increased 
our understanding on the complex oncogenic mechanisms of one of the five ETS 
transcription factors involved in prostate carcinogenesis. 
SUMMARY
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RESUMO 
 
O cancro da próstata constitui a segunda neoplasia mais frequente em homens em 
todo o mundo e é uma causa comum de morbilidade e consequente mortalidade, 
representando um problema importante em saúde pública. Devido à natureza multifocal e 
heterogénea desta doença, torna-se difícil estudar a progressão da mesma bem como definir 
estratégias de prevenção mais eficazes ou melhores formas de tratamento. A falta de 
métodos mais exatos, capazes de diferenciar entre doença indolente e carcinomas mais 
agressivos, reforçou a necessidade de melhor compreender as alterações genéticas 
subjacentes e vias de sinalização por trás do processo de carcinogénese prostática. 
Uma das maiores descobertas na área do cancro da próstata foi a identificação de 
rearranjos genómicos responsáveis pela formação de genes de fusão a envolver a família de 
fatores de transcrição ETS. O TMPRSS2-ERG é o rearranjo cromossómico mais frequente 
presente em quase metade de todos os casos de cancro da próstata, seguido do ETV1, 
ETV4, ETV5 e FLI1 geralmente rearranjados com parceiros 5’ adicionais. Estas alterações 
moleculares, descritas como eventos precoces, são verdadeiramente notáveis e 
representam uma mudança paradigmática na compreensão da tumorigénese prostática.  
Diferentes estudos funcionais têm vindo a abordar questões de redundância e de 
especificidade comummente associadas a cada um dos membros da família ETS, utilizando 
como modelos as linhas celulares. Na sequência destes trabalhos, genes como o ERG, 
ETV1 e ETV5 foram implicados no processo de invasão celular em próstata. Não obstante, 
torna-se igualmente necessário clarificar mecanismos moleculares a envolver rearranjos ETS 
mais raros (como o ETV4 e o FLI1), contudo esta tarefa está condicionada ao escasso 
número de linhas celulares prostáticas com genes de fusão já caracterizados e adequados 
ao tipo de estudo. Desta forma, o presente trabalho tinha como objetivo explorar o 
mecanismo e papel funcional da sobre-expressão de ETV4 em diferentes linhas celulares de 
próstata com e sem rearranjos genómicos conhecidos noutros genes ETS. 
Assim, uma estratégia de análise de expressão quantitativa dos ETS foi inicialmente 
realizada em cinco linhas celulares, representativas dos diversos subtipos moleculares de 
cancro da próstata. Confirmámos a sobre-expressão de ERG e ETV1 nas linhas VCaP e 
LNCaP, respetivamente, bem como sobre-expressão de ETV4 na PC-3. Curiosamente, o 
modelo celular de MDA-PCa-2b apresentou co-sobre-expressão de ETV1 e ETV4. 
Posteriormente, uma análise seletiva por FISH permitiu avaliar a presença de rearranjos 
cromossómicos a envolver o gene ETV4 nas linhas PC-3 e MDA-PCa-2b. A primeira mostrou 
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possuir um rearranjo genómico atípico a envolver o ETV4, ao passo que a última demonstrou 
ter uma translocação equilibrada responsável pela fusão MIPOL1-ETV1, mas nenhum outro 
rearranjo capaz de justificar a sobre-expressão aberrante de ETV4. Adicionalmente, fomos 
estudar os processos biológicos associados à expressão de ETV4 nas duas linhas 
prostáticas que apresentaram sobre-expressão do mesmo – PC-3 e MDA-PCa-2b. Utilizando 
técnicas de silenciamento in vitro, obtivemos não só um decréscimo dos níveis de 
crescimento independente de ancoragem como também de invasão celular nos clones de 
PC-3 silenciados para o ETV4. Quanto à MDA-PCa-2b, os silenciados exibiram uma 
diminuição na capacidade de crescer sob a forma de colónias, contudo mal foram capazes 
de invadir no ensaio de Matrigel. A fim de identificar e caracterizar potenciais genes alvo do 
ETV4, foi utilizado um array de expressão para avaliar o perfil génico das diferentes linhas 
celulares silenciadas. Apesar dos resultados do perfil de expressão destacarem genes ainda 
com funções inexploradas, a maioria está descrita como tendo um papel preponderante no 
ciclo celular ou crescimento celular. Identificámos dois (C1orf129; PAK1IP1) e seis (FTH1; 
KIAA1199; PLK2; SPTLC3; TLL1; TMEM154) genes candidatos sobre- e sub-expressos, 
respetivamente, pelo ETV4 em todas as linhas analisadas.  
Deste modo, a combinação dos resultados obtidos com a análise fenotípica após 
silenciamento e os perfis de expressão revelaram que a sobre-expressão de ETV4 contribui 
para o processo neoplásico e programa de transformação celular de cancro da próstata. Em 
conclusão, este trabalho permitiu-nos aprofundar o nosso conhecimento acerca dos 
complexos mecanismos oncogénicos de um dos cinco fatores de transcrição ETS envolvido 
na carcinogénese prostática. 
 
 
 
RESUMO
 23 
 
LIST OF ABBREVIATIONS 
 
ACSL3 Acyl-CoA synthetase long-chain family member 3 
AKT v-akt murine thymoma viral oncogene homolog 1  
APC Adenomatous polyposis coli 
AR  Androgen receptor  
ASAP Atypical small acinar proliferation 
BAC  Bacterial artificial chromosome  
BAMHI Restriction enzyme derived from Bacillus amyloliquefaciens 
BCA Bicinchoninic acid 
BME Basement membrane extract 
BPH Benign prostatic hyperplasia 
BRCA1 Breast cancer 1, early onset 
BRCA2 Breast cancer 2, early onset 
BSA  Bovine serum albumin  
C15orf21  Chromosome 15 open reading frame 21  
CANT1  Calcium activated nucleotidase 1  
CDH1 Cadherin 1 
CDKN2A Cyclin-dependent kinase inhibitor 2A (p16)  
cDNA Complementary DNA 
CGH Comparative genomic hybridization 
COPA  Cancer Outlier Profile Analysis  
CRPC Castration-resistance prostate cancer 
DDX5  DEAD (Asp-Glu-Ala-Asp) box polypeptide 5  
DHT 5α-dihydrotestosterone 
DMSO Dimethylsulfoxide 
DNA Deoxyribonucleic acid 
DNMT1 DNA Methyltransferase 1 
dNTPs Deoxynucleoside triphosphates 
DRE Digital rectal examination 
EBD ETS binding domain 
EBS  ETS binding site  
EcoRI Endonuclease enzyme isolated from strains of E. coli 
 
      
 
24 
 
ELAC2 elaC homolog 2 
ERG  v-ets erythroblastosis virus E26 oncogene homolog 
ETS E-twenty six 
ETV1 ETS variant 1 
ETV4 ETS variant 4 
ETV5 ETS variant 5  
EZH2 Enhancer of zeste homolog 2 
FBS Fetal bovine serum 
FISH Fluorescent in situ hybridization 
FLI1 Friend leukemia virus integration 1 
FOXP1 Forkhead box P1 
gDNA Genomic deoxyribonucleic acid 
GS  Gleason score  
GSTP1  Glutathione S-transferase pi 1  
GUSB  Glucuronidase beta  
HDAC1  Histone deacetylase 1  
HERV-K  Human endogenous retrovirus  
HGPIN  High grade prostatic intraepithelial neoplasia  
HMT Histone methyltransferase 
HNRPA2B1  Heterogeneous nuclear ribonucleoprotein A2/B1  
HRP Horseradish peroxidase 
HRPC  Hormone refractory prostate cancer  
KLK2  Kallikrein-related peptidase 2  
LGPIN Low grade prostatic intraepithelial neoplasia 
LHRH Luteinising hormone release hormone 
MGMT Methylguanine-DNA methyltransferase 
MIPOL1 Miror-image polydactyly 1 
MMP  Matrix metalloproteinase 
mRNA Messenger RNA 
MSR1 Macrophage scavenger receptor 1  
MTT 3-(4,5-dimethylthiazollyl-2)- 2,5-diphenyltetrazolium bromide 
MYC  Myc myelocytomatosis viral oncogene homolog  
NDRG1  N-myc downstream regulated 1  
NKX3.1  NK3 homeobox 1  
LIST OF ABBREVIATIONS
      
 
25 
 
PBS Phosphate buffered saline 
PCa Prostate cancer  
PCR  Polymerase chain reaction  
PI3K Phosphatidylinositol 3’-kinase-protein kinase B 
PIA  Proliferative inflammatory atrophy  
PIN  Prostatic intraepithelial neoplasia  
PNT  Pointed domain  
PSA  Prostate-specific antigen  
PTEN  Phosphatase and tensin homolog  
PZ Peripheral zone 
qRT-PCR  Quantitative reverse transcriptase-polymerase chain reaction  
RASSF1 Ras association domain family member 1 
RB1 Retinoblastoma 1 
RNA Ribonucleic acid 
RNAi RNA interference 
RNASEL Ribonuclease L 
RT-PCR Reverse transcriptase polymerase chain reaction 
SD Standard deviation 
SDS Sodium Dodecyl Sulfate 
SDS-PAGE Sodium Dodecyl Sulfate Polyacrylamide Gel Electrophoresis 
shRNA Short hairpin RNA 
siRNA Small interfering RNA 
SLC45A3  Solute carrier family 45, member 3  
TBS Tris buffered saline 
TBS-T Tris buffered saline with Tween 20 
TLDA  Taqman low density arrays  
TMPRSS2  Transmembrane protease, serine 2  
TNM  Tumor, node, metastasis  
TP53  Tumor protein p53  
TRUS  Transrectal ultrasonography  
TSG  Tumor suppressor gene  
TZ Transitional zone 
 
 
LIST OF ABBREVIATIONS
      
 
26 
 
 
 27 
 
INTRODUCTION 
 
1. Cancer Knows No Boundaries 
  
Cancer is a colossal global health issue, which accounts for one in eight deaths 
worldwide. It has been quite concerning to see this burden growing at such a frightening 
pace. Based on the GLOBOCAN 2008 estimative, about 12.7 million new cancer cases and 
7.6 million deaths were accounted (Boyle and Levin 2009). It is expected that in 2030, 21.4 
million cancer cases and 13.2 million cancer deaths will occur, mainly due to growth and 
aging of the population combined with an increase of inadequate behaviors and lifestyles 
(Ferlay et al. 2010). 
This human genetic disease arises from the accumulation of a series of changes at the 
DNA level (Stratton et al. 2009), which involve mutations in proto-oncogenes, tumour 
suppressor genes and genes that detect and repair DNA damages (Hanahan and Weinberg 
2000). These topics will be discussed in more detail later on. 
 
 
1.1. Prostate cancer epidemiology 
 
The statistics for prostate cancer recognize it as one of the greatest medical problems 
among the male population, which sets undoubted challenges for oncological research. 
Prostate cancer (PCa) is the second most frequently diagnosed non-skin cancer 
affecting men worldwide and the sixth deadliest cancer, with a total of 903,500 new cancer 
cases registered and a mortality estimated to be over 258,400 in 2008 (Jemal et al. 2011). 
Both incidence and mortality rates of PCa differ substantially between developed and 
developing countries, with higher incidence recorded mainly in North America, Western and 
Northern Europe and Oceania; this is in part due to better and earlier detection by the 
practice of prostate specific antigen (PSA) testing and subsequent biopsy. On the other hand, 
higher mortality is primarily detected in black populations from Caribbean and African regions 
(Figure 1). Differences in genetic variants (Corder et al. 1995; Irvine et al. 1995; Devgan et 
al. 1997; Platz et al. 2000; Shook et al. 2007), serum level of sex hormones (Winters et al. 
2001) and growth factors (Platz et al., 1999; Tricoli et al., 1999; Winter et al., 2001) may 
justify these racial variations in PCa rates. 
      
28 
 
 
Figure 1 – Age-standardized prostate cancer incidence and mortality rates in world area            
Source: GLOBOCAN 2008 (Jemal et al. 2011). 
 
 
Prostate cancer is a slowly growing cancer (Partin et al. 1992; Schmid et al. 1993; 
Virtanen et al. 1999) and incidence and mortality rates tend to increase with age more than 
any other type of cancer (Franceschi and La Vecchia 2001). This effect is dramatically 
observed because of the general aging of world’s population. The proportion of men aged 
over 50 years old is increasing in the West, so the disease is likely to become even more 
prevalent with time. 
In Europe, the major cancer diagnosed in men was by far PCa (382,000, 22.2% of the 
total) succeeded by lung (291,000, 17%) and colorectal (231,000, 13.5%) cancers. In 2008, 
this carcinoma was also responsible for 9.3% of the cancer-related deaths (89,000 cases), 
being the third most common cause of cancer death. In Portugal, PCa constitutes the most 
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incident cancer in men, with 5,140 estimated new cases, and the third cause of            
cancer-associated deaths (2,021 deaths per 100,000 persons) in 2008 (Figure 2). Moreover, 
it represents almost the same relevant proportion of the total number of newly diagnosed 
cases of all cancers as in Europe (11.9%) (Ferlay et al. 2010). 
 
      PORTUGAL, 2008 
 
   
 
Figure 2 – Estimated cancer incidence and mortality in Portugal (adapted from (Ferlay et al. 
2010)). 
 
 
1.2. Etiology and risk factors 
 
The etiology of prostate cancer remains illusive thus far. Many endogenous and 
environmental factors seem to be linked to PCa risk, and some of them have already been 
confirmed by epidemiological studies (Bostwick et al. 2004; Schaid 2004). However, when 
compared with other common cancers, the causes for developing prostate carcinoma are still 
poorly understood. The only well-known established prostate cancer risk factors, beyond PSA 
itself, include age, race/ethnicity and family history (Table 1). 
The relationship between age and the risk of PCa is quite strong, with increasing age 
being predictive of a higher risk of developing the disease, as about 62% of all PCa cases are 
diagnosed in men with more than 65 years old. The probability of a 50-year old white man 
developing PCa is 2.14%, rising to 8.02% in a 70-year old man (American Cancer Society: 
Cancer Facts and Figures 2010). The variability among racial and ethnic groups in the risk of 
developing PCa is also large (Toles 2008). African American men show substantially greater 
probabilities when compared with white men, which is translated in 3.78% and 11.17% at the 
age of 50 and 70 years old, respectively (American Cancer Society: Cancer Facts and 
Number of cancer cases (all ages) 
Males Total: 24,030 
Number of cancer deaths (all ages) 
Males Total: 14,658 
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Figures 2010). It has been suggested that genetics, diet and socioeconomic status are 
contributory factors to this racial differences. 
Another factor is family history, which is also associated with PCa risk (Thiessen 1974; 
Carter et al. 1991), being responsible for 5-10% of prostate cancers at an early age              
(< 55 years old). Men who have first or second-degree relatives with PCa show a two or 
three-fold risk of developing the disease during their lifetime (Bruner et al. 2003; Johns and 
Houlston 2003). One possible explanation for this genetic predisposition may rely on the 
inheritance of high- and low-penetrance genes (Grönberg et al. 1994; Schaid 2004; Wu et al. 
2006). Mutations in high-penetrance susceptibility genes are generally rare though may 
confer a high risk of cancer, whereas mutations or single nucleotide polymorphisms (SNPs) in 
low-penetrance genes may change the risk for the disease modestly (Lichtenstein et al. 
2000). Linkage analysis studies have identified multiple chromosomal loci that may be 
associated with susceptibility for PCa, suggesting that inherited predisposition is 
heterogeneous and can involve distinct genes and variable phenotypic expression (Berry et 
al. 2000). Thus far, elaC homolog 2 (ELAC2), macrophage scavenger receptor 1 (MSR1), 
and ribonuclease L (RNASEL) have been pointed out as high-penetrance genes (Deutsch et 
al. 2004; Porkka and Visakorpi 2004; Dong 2006), but unfortunately they only explain a small 
proportion of PCa genetic predisposition. 
 
Table 1 – Risk factors for PCa (adapted from (Grönberg 2003)). 
 
Risk factors for prostate cancer 
 
Established 
 
Possible 
 
Uncertain 
 
 
Age 
 
Lycopene 
 
AR polymorphisms 
 
 
 
 
Ethnic origin 
 
Zinc 
 
Vitamin D polymorphisms 
 
 
 
 
Family history 
 
Selenium 
 
Dietary fat 
 
 
 
 
 
Recent association studies demonstrated an increase in the frequency of BRCA1 and 
BRCA2 mutations in PCa patients. The rate of PCa in individuals younger than 55 years may 
be especially higher in carriers of germline mutations in BRCA2 (Edwards and Eeles 2004; 
Agalliu et al. 2009).  
 
INTRODUCTION
      
31 
2. Prostate Cancer: Anatomy and Pathology 
 
2.1. Anatomy of the prostate gland 
 
The prostate gland is about the size and shape of a walnut surrounding the urethra at 
the base of the bladder. Its primary function is to secrete a slightly alkaline fluid that forms 
part of the seminal fluid, which provides nutritional support to semen (McNeal 1972, 1988a).  
The prostatic epithelium is composed by four cell types: secretory, basal, transient (an 
intermediate between the previous two (Isaacs and Coffey 1989)) and neuroendocrine cells. 
The first ones are responsible for the physiological secretions of the gland. The basal cells, in 
less abundance, belong to the basement membrane and, when absent, may constitute an 
useful marker of PCa. Finally, neuroendocrine cells are distributed throughout the gland and 
are believed to be involved in the regulation of prostatic secretory activity and cell growth 
(Blacklock 1974; McNeal 1988a). 
In the beginning of the 1980s, McNeal established the most widely and current 
accepted concept of various prostate zones. Although the adult prostate lacks apparent 
lobular structure, his classic work defined the human prostate as having three distinct parts, 
corresponding to the peripheral, transitional and central zones (Figure 3) (McNeal 1981).  
 
 
 
Figure 3 – Zonal anatomy of the normal prostate. (De Marzo et al. 2007). 
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Thereupon, the peripheral zone (PZ) comprises 70% of all prostatic glandular tissue 
and harbors most prostate adenocarcinomas, at the dorsal and dorso-lateral side of the 
organ. In contrast, the transitional zone (TZ), consisting of two equal lateral lobes surrounding 
the urethra, accounts for 5% of the normal prostate volume and gives rise to the majority of 
benign hyperplasia and, far more rare, to carcinomas with lower biochemical recurrence rates 
and less malignant than tumors originating in the PZ (McNeal et al. 1988b; Ziada et al. 1999). 
The central zone is a cone shaped region at the confluence of the ejaculatory ducts and 
represents about 25% of the glandular tissue. Only 5-10% of the cancers develop in this 
region. 
 
 
2.2. Premalignant and malignant prostate lesions 
 
Prostate cancer is a complex, heterogeneous and often multifocal disease (Bostwick 
1989). Evidence indicates that this neoplasia resides histologically for years before clinically 
significant prostate cancer can be detected (Sakr et al. 1994). That is why knowledge and 
understanding of the pathobiology is fundamental to elaborate effective prevention strategies 
or treatment modalities to avoid cancer progression. 
An overwhelming proportion (99%) of all prostate cancers are adenocarcinomas and, 
as described before, the majority (70%) appear in the peripheral zone of the epithelium. 
There are two main types of prostatic disease in adult males, benign prostatic hyperplasia 
(BPH) and prostate cancer. BPH refers to the nonmalignant growth of smooth muscle and 
epithelial cells, representing the most benign androgen-dependent condition found in prostate 
(Hayward et al. 1997). As it progresses in the central area of the organ (TZ zone), around the 
urethra, the pressure exerted can cause lower urinary symptoms that have been the basis for 
diagnosing BPH (Roehrborn 2008). This is almost an universal phenomenon among aging 
men, affecting about 60% and 80% of men over age 60 and 80, respectively (Roehrborn 
2005). On the other side, PCa tends to develop through early and late precancerous 
histologic alterations (Sciarra et al. 2007; De Nunzio et al. 2011). Currently, prostatic 
intraepithelial neoplasia (PIN), high-grade PIN (HGPIN), and atypical small acinar 
proliferation (ASAP) have been identified as precursor lesions to prostatic carcinoma. 
The cancer ancestor PIN, a term that was proposed by Bostwick and Brawer (Bostwick 
and Brawer 1987), is characterized by proliferation of the luminal epithelium, reduction in 
basal cells and augmentation of nuclei/nucleoli ratio, representing an intermediate step 
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between the benign and invasive state (Bostwick et al. 1996). Moreover, two grades of PIN 
have been identified: low-grade PIN (LGPIN) and high-grade PIN (HGPIN) (Figure 4). High-
grade PIN lesion is the only recognized premalignant precursor to prostatic adenocarcinoma 
(Sinha et al. 2004; Joniau et al. 2005), and generally displays benign prostatic acini and ducts 
lined up with atypical cells, whose changes are similar to those of PCa. However, invasion of 
prostatic glands basement membrane does not occur (McNeal 1969). Its incidence 
progressively increases with age preceding the development of carcinoma by 10 years 
(Colanzi et al. 1998; Orozco et al. 1998; Novis et al. 1999). Bostwick et al. have described at 
least four different architectural patterns of HGPIN, i.e. tufted, micropapillary, flat and 
cibriform (Bostwick et al. 1993), which carry equivalent prognostic importance. The same was 
not verified for LGPIN, which seems to have different clinical outcomes than HGPIN. Most of 
these cases do not progress; therefore presence of LGPIN has no longer been reported by 
most pathologists. 
 
 
 
 
Figure 4 – Histopathology of human prostate cancer. (A-D) Hematoxylin-eosin-stained sections of 
PCa. (A) Benign normal tissue, with representative basal (bas) and luminal (lum) cells indicated. (B) 
PIN; arrows indicate regions of hyperplastic epithelium. (C) Well-differentiated adenocarcinoma. (D) 
Poorly differentiated adenocarcinoma. E) Cellular model of early prostate neoplasia progression 
(adapted from (De Marzo et al. 2007; Shen & Abate-Shen 2010)). 
 
The ASAP category includes a group of lesions (lesions of adenosis, atypical 
adenomatous hyperplasia, intraductal hyperplasia, and acinar atypical hyperplasia) that has 
different clinical significance and may mimic cancer, but these morphologic features are not 
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enough to definitively establish a diagnosis of carcinoma (Bostwick and Meiers 2006; 
Montironi et al. 2006). The incidence of ASAP is approximately 2% to 3% in patients 
undergoing needle biopsies of the prostate (Mallén et al. 2006). 
An alternative, possibly earlier, precursor of PCa is proliferative inflammatory atrophy 
(PIA), which is characterized by focal atrophic lesions occurring in association with 
inflammation (Ruska et al. 1998; De Marzo et al. 1999). De Marzo suggested that PIA could 
be a potential precursor to prostatic adenocarcinoma via development into HGPIN (Putzi and 
De Marzo 2000; De Marzo et al. 2003), but this model is questioned by other authors and 
results of pathological studies are inconclusive (Billis 1998; Billis & Magna 2003; Di Silverio et 
al. 2003). 
Finally, prostate adenocarcinoma (PCa), which accounts for more than 95% of all 
malignancies of the prostate (DeVita et al. 2008), is an age-related condition with an initial 
reliance on androgens for development, growth and survival (Carroll et al. 2002; Culig and 
Bartsch 2006). Most of them arise in the posterior outer zone of the prostate and, with 
passage of time, often develop a tremendous heterogeneity and a multifocal pattern (Hricak 
and Scardino 2008). 
 
 
3. Hormonal Environment in Prostate Cancer 
 
3.1. Androgens in prostate cancer 
 
Increased levels of androgens have long been linked to both prostatic development and 
prostatic carcinogenesis (Gelmann 2002). As a matter of fact, androgens serve as important 
ligands for PCa, stimulating growth via the androgen receptor (AR) pathway. 
The revolution started 70 years ago, when Charles Huggins and colleagues established 
that prostate cancer was an androgen-dependent malignancy (Huggins and Hodges 1941). 
Since then, relevant research has been made in unraveling the mechanisms of androgen 
action and its relation with different signaling cascades, culminating into alternative hormone 
therapy treatments. 
The two main androgens in humans are testosterone and 5α-dihydrotestosterone 
(DHT). The first one is the most abundant circulating androgen and, once catalyzed by the 
5α-reductase enzyme, is often converted into a more potent androgen – the DHT (Russell 
and Wilson 1994; Andriole et al. 2004; Imamoto et al. 2008). Both testosterone and DHT are 
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capable of binding to AR, a member of the steroid nuclear receptor superfamily, however 
DHT displays a higher binding affinity and stabilization of the AR complex than its precursor, 
testosterone (Zhou et al. 1995; Wright et al. 1996; Tindall and Rittmaster 2008). Upon 
binding, these complexes are phosphorylated, dimerized and translocated to the nucleus, 
where they bind to specific DNA sites in the promoter of androgen-responsive target genes 
activating their transcriptional activity. 
 
 
3.2. Moving towards an androgen-independent status 
 
At early stages, prostate cancer cells are mostly dependent on androgen and, 
therefore, respond to adequate androgen ablation therapies (Denis and Griffiths 2000). 
Despite the efforts to reduce tumor burden and AR activity, these treatments eventually fail 
and PCa shifts to an androgen-independent state that represents one of the most indicative 
aspects of disease progression. A possible explanation for the rising of this androgen-
independent population might be a clonal selection mechanism. Over time, via selective 
growth of pre-existing clones, androgen-independent tumor cells emerge and ultimately 
predominate during hormonal therapy while continuing to proliferate (Isaacs 1999). Such 
transition also appears to involve up-regulation of genes capable of promoting cell survival 
and growth after androgen deprivation, along with AR mutations and its interaction with other 
transcriptional factors (Figure 5) (Visakorpi et al. 1995; Feldman and Feldman 2001).  
Once patients develop resistance, hormone treatment strategies are no longer effective, 
which leads to a poor prognosis with an average expected survival period of 17 months (Kish 
et al. 2001; Petrylak et al. 2004; Loblaw et al. 2007). Despite this handicap, newer targets 
and drug combinations are being identified in order to improve response rates. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 – The mutant androgen receptor (AR) 
can be activated by a variety of steroid 
hormones, antiandrogens, and growth factors 
(Ruijter et al. 1999). 
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4. Diagnosis of Prostate Cancer 
 
Prostate cancer is a very unreliable disease since it may develop within and outside the 
prostate before giving any symptoms. Therefore, detection at an early and asymptomatic 
stage is essential, as the patient’s chances of cure are higher.  
The most widespread screening tests, commonly used in a routine medical check-up,  
are serum measurement of prostate-specific antigen (PSA) and digital rectal examination 
(DRE), before any biopsy is made. 
 
 
4.1. PSA testing 
 
PSA is a serine protease produced primarily in the epithelium and ducts of the prostate 
gland and its main function is to liquefy the semen (Lilja et al. 1987; Yousef and Diamandis 
2001). The highest levels of PSA are found in the seminal fluid, however this protein may 
escape the prostate and gain access to the bloodstream (Wang et al. 1981; Lövgren et al. 
1999). This phenomenon is possibly explained by the disruption of prostate’s basal cell layer 
and basement membrane, which represents a characteristic early feature of PCa. The loss of 
normal glandular architecture seems to permit PSA increased access to the peripheral 
circulation (Brawer et al. 1989; Bostwick 1994; Balk et al. 2003).  
The PSA test measures the level of PSA in serum, and is currently used as a biomarker 
of PCa having revolutionized the management of prostate disease (Stamey et al. 1987). 
However, it still lacks specificity and cannot differentiate between clinically insignificant and 
aggressive disease. PSA can be increased in conditions such as BPH and prostatitis, and 
conversely can be low in the presence of PCa. Nevertheless, the normal range limit 
established for total PSA is 4ng/mL (Catalona et al. 1991). There is agreement that men with 
a total PSA level superior to 10ng/mL have a greater risk for PCa (with more than 67% 
chance, according to the American Cancer Society), whereas PSA values between 4-
10ng/mL, often referred to as the diagnostic “gray zone”, may indicate PCa, BPH, or 
prostatitis. Thus, men with PSA ˃ 4ng/mL will be considered candidates for prostate biopsy to 
confirm the presence of cancer, and only 20-30% of them will be found to have PCa 
(Emiliozzi et al. 2001; Wolf et al. 2010). Moreover, men with PSA levels inferior to 4ng/ml 
should not be biopsied, though several studies reported that low levels of PSA do not rule out 
the possibility of prostate disease (Catalona et al. 1999; Roehl et al. 2002). Therefore, 
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encouragement for lowering the cutoff levels that determine if a PSA value is normal or 
elevated has been emphasized over the years, still some researchers argue that this would 
aggravate over-diagnosis and over-treatment of cancers that are not clinically significant.  
It is important to understand that the PSA test lacks the sensitivity and specificity to 
detect early-stage tumors. Besides, PSA has turned out to be only organ specific, not 
prostate cancer specific. Several approaches have been suggested to improve the accuracy 
of total PSA, including measurement of PSA velocity, levels of free and complexed PSA, age-
specific PSA and its density (Greene et al. 2009). However, the clinical utility of these 
methods remains uncertain. 
 
 
4.2. Digital rectal examination (DRE) 
 
Before the advent of serum prostate-specific antigen (PSA) testing in 1986, the digital 
rectal examination (DRE) was the sole tool of screening men for prostate cancer. But this test 
alone is not sensitive enough to detect the small-volume tumors that are most amenable to 
cure. It can only identify a small proportion of tumors (9%), which end up to be at advanced or 
metastatic stages (Chodak et al. 1989; Smith and Catalona 1995; Hoogendam 1999). For this 
reason, it is important to combine this method with PSA testing in order to increase the 
diagnostic yield of prostate cancer. 
 
 
4.3. Transrectal ultrasound-guided core biopsy 
 
Regardless the utility of diagnostic aid-tools, the standard way to diagnose prostate 
cancer is by obtaining material for a histopathological examination of the prostatic gland 
through needle core biopsy with guidance by transrectal ultrasound (Terris 2002). Modern 
needle biopsy techniques show low morbidity and provide more specific information about the 
grade and tumor extension than does fine-needle aspiration. The difficulty with needle biopsy 
resides in the small amount of tissue available for histological analysis and the possible 
difficulty of identification of few malignant glands among many benign glands (Epstein 1995). 
Today, transrectal ultrasonography (TRUS) has become a helping tool on guiding the biopsy 
needles into the right area of the prostate, allowing to estimate its size and to diagnose and 
stage the cancer. The scheme used at first biopsy should be a 10 to 12 core pattern in order 
to increase PCa detection rate (Eichler et al. 2006; Hara et al. 2008a). 
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4.4. Prognosticators 
 
In both radical prostatectomy and needle biopsy samples, histological grading and 
staging are the two most commonly used prognostic factors for prostate cancer (Kattan et al. 
1998; Epstein et al. 2006). 
 
 
4.4.1. Histopathological evaluation 
 
When cancer develops, the glands multiply and change their architectural pattern. Such 
range of patterns has been classified under the Gleason grading system, named after the 
pathologist who first proposed the system (Gleason 1966). The classic Gleason grading 
describes the histologic appearance of PCa under low magnification and recognizes five 
patterns of grades of cancer on a scale from 1 (a well differentiated grade with mild structural 
changes) to 5 (poorly differentiated with full disappearance of glandular structure) (Figure 6). 
The clinical relevance of this system is its ability to predict aggressiveness and disease 
outcome. 
 
 
Figure 6 – The original Gleason scoring 
showing grades 1-5 (Gleason 1966). 
 
Grade 1 – closely resemble small, uniform 
glands. 
Grade 2 – more stroma between the glands. 
It may minimally invade non-neoplasic 
tissue. 
Grade 3 – is the most frequent grade 
characterized by irregular size glands with 
angular shape and more infiltrative margins. 
Grade 4 – possibly the most important grade 
since it is rather frequent, presenting fused, 
cribiform or poorly defined glands. 
Grade 5 – more associated with poor 
prognosis, characterized by a complete loss 
of glandular structures. 
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As PCa is usually histologically heterogeneous, Gleason came up with the idea of 
incorporating the two most common or dominant grades into the system, establishing the 
Gleason score (GS). It consists in the addition of the primary pattern (the most prevalent) with 
the secondary grade (next most common pattern), allowing to better predict the prognosis of 
any particular patient. Consequently, the Gleason score ranges from 2 to 10 (Gleason and 
Mellinger 1974). In general terms, a Gleason score 2 to 6 tumor has a relatively good 
prognosis since it is well differentiated, a Gleason 7 tumor is moderately to poorly 
differentiated and has an intermediate prognosis, and a Gleason 8 to 10 tumor is poorly 
differentiated and associated with a poor prognosis. Score 7 tumors can be subclassified into 
4+3 or 3+4, having the former the worst prognosis. Thus, the higher the score the more 
aggressive the tumor is and the more likely is a poor outcome for the patient (Humphrey 
2004).   
 
 
4.4.2. Staging systems 
 
The practice of staging solid tumors relies on the TNM (tumor-lymph node-metastasis) 
classification to evaluate patient’s prognosis and to help define the appropriate therapy. The 
TNM system is based on the assessment of three components, in order to describe the 
anatomical extent of the disease: a T number (T1 to T4) that characterizes the extent of the 
primary tumor, a N number (N0 or N1) that indicates whether the cancer has metastized to 
the lymph nodes, and a M number (M0 or M1) that describes the presence or absence of 
metastasis in distant sites (Chisholm et al. 1994; Greene and Sobin 2002). It also includes a 
clinical and a pathological classification, the former is designated TNM or cTNM and it is 
defined based on evidence obtained prior to treatment from physical examination, imaging or 
biopsy. The latter, named pTNM, is a postsurgical histopathological classification that 
estimates prognosis (pT, pN, pM) (Table 2) (Edge and Compton 2010). 
In short, stages T1 and T2 are organ-confined cancers, whereas stage T3a and T3b 
tumors show extra-prostatic extension, with and without seminal vesicle invasion, 
respectively. Finally, stage T4 reflects direct invasion of nearby organs (Yarbro et al. 1999). 
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Table 2 – Overview of the TNM staging system for PCa (adapted from (Edge and Compton 2010)). 
 
Extent of Primary Tumor (T) 
Clinical Tumor Stage (cTNM) 
Tx Primary tumor cannot be assessed 
T0 No evidence of primary tumor 
T1 Clinically unapparent lesion (by palpation or imaging studies) 
T1a Involvement of ≤5% of resected tissue 
T1b Involvement of >5% of resected tissue 
T1c Carcinoma present on needle biopsy (following elevated PSA) 
T2 Palpable or visible cancer confined to prostate 
T2a Involvement of less than one-half of one lobe 
T2b Involvement of more than one-half of one lobe, but unilateral 
T2c Involvement of both lobes 
T3 Local extraprostatic extension 
T3a Extracapsular extension 
T3b Seminal vesical invasion 
T4 Invasion of contiguous organs and/or supporting structures including bladder 
neck, rectum, external sphincter, levator muscles, and/or pelvic wall 
Pathological Tumor Stage (pT) * 
pT2 Organ confined 
pT2a Involvement of less than one-half of one lobe 
pT2b Involvement of more than one-half of one lobe, but unilateral 
pT2c Bilateral disease 
pT3 Extraprostatic extension 
pT3a Extraprostatic extension or microscopic invasion of bladder neck 
pT3b Seminal vesical invasion 
pT4 Invasion of rectum, levator muscles and/or perlvic wall 
Status of Regional Lymph Nodes (N) 
Clinical Tumor Stage 
Nx Regional lymph nodes were not assessed 
N0 No regional nodal metastasis 
N1 Metastasis in regional lymph nodes 
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Pathological Tumor Stage (pN) 
pNx Regional nodes not sampled 
pN0 No positive regional nodes 
pN1 Metastasis in regional node(s) 
Distant Metastases (M) 
M0 No distant metastasis 
M1 Distant metastasis present 
M1a Metastases to distant lymph nodes 
M1b Bone metastases 
M1c Other distant sites 
 
* There is no pathologic T1 classification 
 
 
Several studies show that grade, stage, and PSA are strong prognostic factors. 
According to these characteristics, patients can be organized into risk groups. This 
categorization model stratifies patients with prostate cancer into those with low, intermediate, 
or high-risk of relapse after a definitive therapy (D’Amico et al. 1998). Men that belong to a 
low risk group have a PSA ≤ 10ng/mL, GS ≤ 6 and T1c to T2a stage disease, while those with 
a PSA level between 10-20ng/mL, GS = 7 and a clinical stage T2b fit into the intermediate 
risk group; high risk patients have a PSA ≥ 20ng/mL, GS ≥ 8 and/or stage T2c-3a disease 
(Thompson et al. 2007). 
As such, this could potentially help making a more informed treatment selection. 
However, as this system is not perfect, identification of new biomarkers with diagnostic and 
prognostic significance would still allow a better therapeutic decision for these patients. 
 
 
5. Prostate Cancer Treatment 
 
Currently, there are many treatment options available for prostate cancer that need to 
be adapted to the individual patient. Localized prostate cancer is usually treated using 
approaches such as watchful waiting, radical prostatectomy, brachytherapy and radiotherapy 
(Heidenreich et al. 2011), whereas metastatic and advanced prostate cancer relies on 
hormonotherapy, radio and chemotherapy options (Mottet et al. 2011). These last options are 
merely palliative rather than curative. 
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5.1. Watchful waiting 
 
Also known as expectant management, it refers to the process of closely monitoring 
disease activity by performing  the PSA and DRE tests regularly, with active treatment offered 
only to men whose disease symptoms appear to be progressing or when metastatic disease 
development is evident (Choo et al. 2002). This management approach is suitable for men 
with low or intermediate grade localized tumors (Walsh 2003; Bill-Axelson et al. 2008). 
 
 
5.2. Radical prostatectomy 
 
Surgical removal of the prostatic gland and seminal vesicles is the only curative 
treatment for clinically localized prostate cancer (Aus et al. 2005). It is a well-tolerated 
procedure by men who have at least a 10-year life expectancy and low comorbidities, unlike 
patients older than 70 years who are not generally considered for prostatectomy (Albertsen et 
al. 1998). 
Apparently, some cases of PCa are clinically over-staged and can be cured with 
surgery alone. The remaining patients with locally advanced disease are identified and can 
be offered adjuvant therapy (Corral and Bahnson 1994; Huland 2001). 
 
 
5.3. Radiotherapy 
 
Contemporary radiation therapy has long been the standard option for men with 
advanced localized cancer who are no longer candidates to undergo radical prostatectomy, 
mainly due to advancing age, a high risk of not achieving surgical complete clearance or 
patient preference. 
Radiotherapy can be effectively delivered by external beam therapy or brachytherapy. 
The first uses an external irradiation dose-escalated scheme that offers the same long-term 
survival results and a quality of life at least as good as surgery (Fowler et al. 1996). The 
second involves interstitial implantation of radioactive seeds in the prostate and is offered to 
patients with clinically localized, low-volume and low-grade disease (Norderhaug et al. 2003). 
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5.4. Hormonotherapy 
 
Most patients with early metastatic disease are treated with androgen-deprivation 
therapy, since curative intent is no longer an option. In general, androgen-deprivation induces 
a remission in 80-90% of men at this stage of the disease, and results in a median 
progression-free survival of 12 to 33 months (Denis and Murphy 1993). 
A number of alternative methods have become available for achieving castrate 
testosterone levels either by suppressing the secretion of androgens or by inhibiting the 
action of androgen circulation at the level of their receptor through bilateral orchiectomy, 
luteinizing hormone release hormone (LHRH) agonists, anti-androgens and oestrogens 
(Geller 1993; Kish et al. 2001). The major consequence observed will be a marked reduction 
of androgen-responsive cancer cells, however this curative potential is limited because of the 
inherent heterogeneity of PCa and the inability of hormones to eradicate all prostate cancer 
clones, both the androgen-dependent and androgen-independent components. Nevertheless, 
the response to therapy can be monitored by changes in PSA level, therefore a decline of 
more than 50% in serum testosterone levels is a common feature of effective therapy in this 
disease (Kelly et al. 1993). More recently, hormonal therapy has been offered as adjuvant 
therapy in combination with radical prostatectomy or radiotherapy, but only for the latter case 
it has shown an improvement in survival (Jani and Hellman 2003). 
 
 
5.5. Chemotherapy 
 
The progression of metastatic androgen-independent prostate cancer to a truly 
hormone-refractory condition constitutes the final stage of the disease and represents a 
threat of morbidity and mortality. For many years, the rates of objective clinical response of 
prostate cancer to available cytotoxic agents were disappointingly poor (Yagoda and Petrylak 
1993). Recently, certain combinations of chemotherapy with taxols have shown limited 
promise in some cases. In fact, many of these are undergoing comparative clinical trials, 
namely docetaxel alone or combined with estramustine, which has already demonstrated to 
improve the survival of men with hormone-refractory prostate cancer in comparison with 
mitoxantrone and corticosteroids (Gilligan and Kantoff 2002; Petrylak et al. 2004; Tannock et 
al. 2004; Schröder et al. 2009; Hugosson et al. 2010). 
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6. The Prostate Cancer Genetics Puzzle 
 
It is generally accepted that the development of tumors involves a multi-step model, 
which is driven by the accumulation of genetic and epigenetic alterations (Hanahan and 
Weinberg 2000). Latest advances in basic research and novel technologies have allowed 
increased understanding on the mechanisms involved in prostate cancer initiation and 
progression. 
Various studies have documented early molecular events associated with development 
of this disease, namely somatic mutations, gene deletions, gene amplifications, chromosomal 
rearrangements and changes in DNA methylation (Abate-Shen 2000; Chin and Reiter 2004; 
De Marzo et al. 2004). 
 
 
6.1. Epigenetic alterations 
 
Epigenetics is the study of heritable changes in gene function that occur without a 
change in the DNA sequence. Because these alterations are known to be very common in 
prostate cancer, this area of research is, at least in theory, an exciting field of potential for 
drug development. The two most important and well studied epigenetic mechanisms are DNA 
methylation (hyper or hypo) and histone modifications, which play essential roles, both 
independently and cooperatively, in gene expression regulation and in tumorigenesis 
(Feinberg and Tycko 2004). 
DNA hypermethylation of regulatory regions of certain genes is a well-established 
epigenetic abnormality seen during prostate cancer progression (Li et al. 2005). A fine 
example of this somatic inactivation is the hypermethylation of the glutathione S-transferase 
pi 1 gene (GSTP1) (Lee et al. 1994). This phase II metabolic enzyme, which plays an 
important role in the detoxification of carcinogens and inflammatory oxidants in prostate cells, 
is expressed and unmethylated in normal epithelium. However, once hypermethylation of the 
promoter occurs, silencing is observed in more than 90% of prostate cancers, as well as 70% 
of HGPIN and 6.4% of PIA (Jerónimo et al. 2001; Nakayama et al. 2003; Hanson et al. 2006), 
which appears to be responsible for prostate cells’ vulnerability to somatic alterations upon 
chronic exposure to genome-damaging stresses. GSTP1 methylation levels discriminate 
between benign and malignant prostate by methylation-specific polymerase chain reaction 
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assay and may be useful as a cancer-specific molecular biomarker (Harden et al. 2003; 
Gonzalgo et al. 2004; Henrique and Jerónimo 2004; Jerónimo et al. 2004). 
In addition, hypermethylation of the tumor suppressor gene APC has also been 
reported to occur in the early stages of PCa, as well as of other genes involved in diverse 
cellular processes such as hormonal response (AR), cell cycle control (CDKN2A), tumor 
invasion (CDH1), DNA repair (MGMT), and signal transduction (RASSF1) 
(Yegnasubramanian et al. 2004; Li et al. 2005; Schulz and Hoffmann 2009). Hypomethylation 
is a second type of methylation defect that contributes to oncogenesis through generation of 
chromosome instability, reactivation of transposable elements, and loss of imprinting (Das 
and Singal 2004; Yegnasubramanian et al. 2008). 
Histone modifications, such as acetylation and methylation, have been widely studied 
due to their association with gene transcription, DNA repair and replication, and chromosome 
organization (Bernstein et al. 2007; Esteller 2007). Some of the already described changes in 
prostate cancer involving histone modifying enzymes combine the HDACs (e.g., HDAC1), 
DNMTs (e.g., DNMT1) and HMTs (e.g., EZH2), that seem to be associated with disease 
prognosis (Li 2007; Weichert et al. 2008; Cooper and Foster 2009; Song et al. 2011;). 
Currently, epigenetic drugs lack gene specificity and some are associated with 
significant toxicity. Hence, efforts are being made to develop gene specific epigenetic drugs 
to prove their efficiency in the treatment of prostate cancer patients (Miyamoto and Ushijima 
2005). 
 
 
6.2. Chromosomal alterations 
 
Altered chromosomal regions in prostate cancer have been studied with several 
techniques, such as karyotyping, fluorescence in situ hybridization (FISH), chromosome 
comparative genomic hybridization (CGH), and, more recently, genome-wide array CGH. 
CGH analyses enabled a better detection of chromosome and gene copy number changes, 
allowing the identification of the predominant genomic loci involved in PCa (Kallioniemi et al. 
1992; Cowell and Nowak 2003; Shinawi and Cheung 2008; Ishkanian et al. 2009). 
Overall, studies have shown that the most common chromosomal abnormalities are 
losses of 6q, 8p, 10q, 13q and 16q, and gains of 7p, 7q, 8q and Xq (Alers et al. 2000; Ribeiro 
et al. 2006; Saramäki et al. 2006; Sun et al. 2007). Losses tend to be more common than 
gains earlier in carcinogenesis, suggesting that inactivation of tumor-suppressor genes is a 
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more important phenomenon in early PCa than amplification of oncogenes (Elo and Visakorpi 
2001), while gains of chromosomal segments become more frequent in advanced cases 
(Nupponen and Visakorpi 1999). Furthermore, deletions of 8p and 10q seem to be correlated 
with tumor grade and stage, whereas strong associations between gain of 8q with disease-
specific survival have been demonstrated (Alers et al. 2000; Ribeiro et al. 2006; El Gammal 
et al. 2010; Barros-Silva et al. 2011). 
 
 
6.3. Somatic genetic alterations 
 
Knowledge of genetic alterations underlying the initiation, development, and 
progression of prostate cancer is accumulating rapidly. The acquisition of the neoplastic 
phenotype seems to rely on both loss and gain of specific regions of tumor suppressor genes 
and proto-oncogenes, respectively. 
 
 
6.3.1. Tumor suppressor genes 
 
Various tumor suppressor genes (TSG’s) have been reported as being involved in 
sporadic prostate tumors (Hughes et al. 2005). The most commonly associated with loss-of-
function are PTEN and NKX3.1. 
The PTEN gene (phosphatase and tensin homologue), located at 10q23, is a TSG that 
encodes a phospholipid phosphatase that negatively controls the phosphatidylinositol 3’-
kinase-protein kinase B (PI3K/AKT) signaling pathway. This regulation normally restricts cell 
growth and survival signals, allowing for normal cell death. Thus, loss of PTEN function will 
lead to a decreased sensitivity to apoptosis (Wu et al. 1998; Sun et al. 1999). On the other 
hand, this TSG has showed to be deleted or mutated in roughly 40% of advanced prostate 
cancers (Li et al. 1997; Wang et al. 1998) and in 5-27% of the primary tumors, being 
correlated with a high Gleason score and advanced stage (McMenamin et al. 1999).  
Another gene worth mention is the NKX3.1 (NK3 homeobox 1). It is one of the most 
promising candidate tumor suppressors examined on chromosome 8p, whose loss is 
frequently observed in prostate cancer. This homeobox gene appears to be essential for 
normal prostate development and stimulates the transcription of prostate-specific genes 
(Bieberich et al. 1996; Bhatia-Gaur et al. 1999; Steadman et al. 2000).  NKX3.1 deletion or 
loss of function was reported in 20% of PIN lesions, 34% of androgen-independent cases and 
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78% of prostate cancer metastases, which is why it has been considered to be associated 
with disease progression (Bowen et al. 2000). Undoubtedly, this gene has drawn specific 
attention due to its attracting role as a gatekeeper, however molecular analyses have not yet 
shown any mutation in its coding sequence (Voeller et al. 1997). 
Other classic tumor suppressor genes, which are genetically inactivated at some 
frequency in metastatic and hormone-refractory lesions include TP53, RB1, and CDKN2A, 
suggesting a role of prostate cancer progression for these genes. 
 
 
6.3.2. Oncogenes 
 
Some somatic gain-of-function changes have already been identified in prostate cancer, 
but the most frequent oncogenic changes are amplifications at the 8q24 and Xq11 loci. These 
regions harbor putative target genes, namely MYC and AR, well known proto-oncogenes. 
The MYC gene (avian v-myc myelocytomatosis viral oncogene homolog) is a member 
of the basic helix-loop-helix-leucine zipper family of transcription factors involved in cell cycle 
progression, apoptosis and cellular transformation (Lavigne et al. 1998; Grandori et al. 2000). 
Both overexpression and amplification of MYC have been shown to be more prevalent in 
recurrent tumors and in metastatic lesions than in primary tumors. The 8q24 gain was, later 
on, demonstrated to be correlated with high histological grade and a predictor of poor survival 
in prostate cancer patients (Buttyan et al. 1987; Jenkins et al. 1997; Sato et al. 1999; Ribeiro 
et al. 2007). Still, a recent study has described upregulation of nuclear MYC protein 
expression in PIN lesions and the majority of carcinomas in the absence of gene amplification 
(Gurel et al. 2008), which places it in the panel of early oncogenic events driving PCa 
progression. 
Another gene implicated in recurrence of PCa is the androgen receptor (AR), located on 
Xq11, whose amplification is observed in about 30% of hormone-refractory tumors (Visakorpi 
et al. 1995; Bubendorf et al. 1999). It is not entirely clear which mechanism explains the 
involvement of AR overexpression and amplification in the genesis of androgen-independent 
tumor growth, but still new target signaling therapies are being heavily investigated to 
overcome this status. 
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7. The ETS Genes and their Role in Prostate Cancer 
 
One of the latest breakthroughs in cancer research was the identification of genomic 
rearrangements responsible for the formation of gene fusions in common solid tumors. The 
clinical relevance of these events in malignant epithelial tumors has been limited because it 
has so far been mostly studied in hematological disorders and sarcomas. However, recent 
experimental evidences suggested the presence of recurrent gene fusions in prostate cancer, 
which are now known to involve several members of the ETS family of transcription factors 
(reviewed in (Kumar-Sinha et al. 2008; Clark and Cooper 2009)). These findings are truly 
remarkable and represent a paradigmatic shift in the understanding of carcinoma 
pathogenesis. 
 
 
7.1. ETS family of transcription factors 
 
The ETS (E26 transformation-specific) family of transcription factors is one of the 
largest families of transcription regulators that has been implicated in several biological 
processes, including cellular proliferation, apoptosis, differentiation, tissue remodeling, 
angiogenesis and oncogenic transformation (Dittmer and Nordheim 1998; Verger and 
Duterque-Coquillaud 2002; Hsu et al. 2004; Seth and Watson 2005). 
The first founding oncogene member of the ETS family, v-ets, was initially discovered in 
1983 as part of a fusion protein expressed by the avian transforming retrovirus E26 (Leprince 
et al. 1983; Nunn et al. 1983). Since then, many cellular homolog related proteins have been 
identified in a variety of species and, so far, there are 27 ETS family members already 
characterized in humans (Graves and Petersen 1998; Oettgen 2000). 
All ETS proteins contain an evolutionary conserved ETS domain of ~ 85 aminoacids, 
which recognizes unique DNA sequences with enriched 5’-GGAA/T-3’ core motifs (ETS 
binding site, EBS) in promoter regions of target genes (Donaldson et al. 1994; Sharrocks et 
al. 1997). The second most conserved domain, found in 11 of the 27 human ETS genes, is 
the pointed (PNT) domain. This 65-85 aminoacid region has been shown to function in 
protein-protein interaction and oligomerization (Karim et al. 1990; Klambt 1993; Wasylyk et al. 
1993) (Figure 7). On the basis of their structural composition and similarities in the DNA 
binding ETS domains, mammalian ETS factors have been organized into several subfamilies 
of more highly related members (Hollenhorst et al. 2007). 
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ETS: DNA binding domain, HLH: helix-loop-helix domain (Pointed domain), AD: activation domain, RD: repression domain 
 
Figure 7 – Protein structures and tissue distributions of major ETS transcription factors. ETS 
factors are divided into several subfamilies based on homology within the ETS DNA binding domain. 
Some ETS have an HLH domain necessary for protein-protein interactions. Several members are 
expressed predominantly in certain types of tissues, and others ubiquitously (Oikawa 2004). 
 
Moreover, ETS proteins are known to act either as transcription activators or repressors 
of the expression of more than 200 target genes, depending on the signaling inputs, the type 
of promoter and the cellular context where they are involved (Sementchenko and Watson 
2000). Nowadays, over 400 ETS target genes have been reported based upon the presence 
of ETS binding sites in their regulatory regions. 
The various members of this family exemplify a specificity problem and overlapping 
expression. As mentioned before, this is often due to their capacity to recognize a short 6-8bp 
core binding sequence, which allows for the occurrence of too many potential binding sites in 
the genome. Nevertheless, genetic experiments have indicated unique biological functions for 
individual ETS proteins (Sharrocks 2001; Oikawa and Yamada 2003; Hollenhorst et al. 
2011a). Phylogenetic analysis based upon the ETS domain sequence homology have 
classified  these factors into 12 different subgroups and four distinct classes according to the 
ETS-domain DNA-binding specificities (Hollenhorst et al. 2007; Wei et al. 2010) (Figure 8). 
INTRODUCTION
      
50 
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 8 – Conservation of mammalian ETS domains. (A) A dendogram showing the degree of 
relatedness of human ETS domain sequences. Branches that separate an individual subfamily are 
labeled in red. Classes defined by differences in the in vitro derived binding site are indicated by 
background colors. (B) ETS domain consensus binding sites (Hollenhorst et al. 2007; Hollenhorst et al. 
2011a). 
 
 
During cancer progression, ETS genes show altered expression patterns that result in 
the deregulation of their target responsive genes, increasing the impact on oncogenic 
transformation. Acquisition of point mutations, genomic amplification, loss or rearrangements 
by these family of transcription factors have been found in most human neoplasias (Seth and 
Watson 2005). Novel results on gene-expressing signatures allowed correlation between 
expression of ETS factors, ETS target genes and prostate cancer progression            
(Tomlins et al. 2007a). 
Considering that some ETS play important roles in maintenance of the transformed 
phenotypes of tumor cells, their usefulness as molecular targets for cancer gene therapy 
could be quite interesting, allowing new approaches to be developed in a near future. 
A B 
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7.2. Discovery of ETS gene fusions in prostate cancer 
 
Gene fusion events are correlated with ectopic and elevated expression of the chimeric 
mRNA, therefore the search for genes with aberrant expression in subsets of tumor samples 
may allow the identification of candidate gain-of-function cancer genes. 
In 2005, Petrovics et al reported frequent overexpression of ERG (v-ets erythroblastosis 
virus E26 oncogene like) mRNA, an ETS-related gene, in clinical prostate cancer samples. 
Interestingly, ERG mRNA expression was higher in patients with less aggressive prostate 
cancers than in those with more aggressive tumors (Petrovics et al. 2005). However, the 
opportunity to find a possible molecular mechanism responsible for this outlier expression 
was overpassed by Tomlins and colleagues later that year (Tomlins et al. 2005). They 
developed a bioinformatics approach denoted Cancer Outlier Profile Analysis (COPA), a 
method used to identify outlier profiles in gene expression data sets, capable of searching for 
genes markedly overexpressed (Rhodes et al. 2004; Rubin and Chinnaiyan 2006). It 
successfully revealed two strong high-ranking and non co-existent profiles across 50% to 
70% of prostate cancer samples, namely ERG (21q22.3) and ETV1 (ETS-variant gene 1; 
7p21.2), members of the ETS family of transcription factors known to be involved in fusions in 
other types of tumor. This exclusiveness is consistent with the idea that ETS gene 
overexpression is an early event that drives prostate cancer development. 
Characterization of cases with aberrant expression of these two genes led to the 
identification of fusions with the 5’ untranslated region of the prostate-specific androgen-
induced transmembrane protease serine 2 gene (TMPRSS2; 21q22.3) (Lin et al. 1999; 
Oikawa and Yamada 2003). This serine protease donates the transcription regulating 
sequences to the coding sequences of ERG, leading to its altered overexpression.   
Collective studies showed that the TMPRSS2-ERG fusions appear to account for the majority 
of occurrences (50-80%), with ETV1 accounting for up to 20% (Cerveira et al. 2006; Soller et 
al. 2006; Cai et al. 2007). These results have been corroborated by several other groups 
(Hermans et al. 2006; Iljin et al. 2006; Perner et al. 2006; Wang et al. 2006; Mehra et al. 
2007; Rouzier et al. 2008). 
Since the discovery of TMPRSS2-ETS fusions, multiple novel 5’ and 3’ fusion partners 
and splice isoforms have been reported, with variable associations with prostate cancer 
(Clark and Cooper 2009). This progress marks a major milestone towards defining molecular 
mechanisms during prostate carcinogenesis (Kumar-Sinha et al. 2008). 
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7.2.1. TMPRSS2-ERG fusion variants 
 
TMPRSS2 and ERG are disposed in the same orientation on chromosome band 21q22, 
separated only by ~ 3 Mb (megabases) of genomic sequence. The fusion transcripts can 
occur either through interstitial deletion of the intervening sequence (Tu et al. 2007; Attard et 
al. 2008a; Yoshimoto et al. 2008; Mani et al. 2009) or undergo a more complex 
rearrangement like an interchromosomal insertion (Teixeira 2008). Each mechanism has 
approximately a 50% chance of occurring (Yoshimoto et al. 2006; Mehra et al. 2008). 
There have been described several types of TMPRSS2-ERG fusion transcripts 
involving different exons of both genes (Clark et al. 2007; Clark et al. 2008a; Furusato et al. 
2008; Hu et al. 2008; Wang et al. 2008; Gopalan et al. 2009). Almost all of these fusion 
transcripts encode truncated ERG proteins which lack the ETS domain. The most frequently 
detected splice variant is between TMPRSS2 exon 1 and ERG exon 4, followed by a fusion of 
TMPRSS2 exon 2 to ERG exon 4 (Hu et al. 2008; King et al. 2009) (Figure 9). 
Of note, a high frequency of ERG wild-type splicing variants has also been identified 
(Duterque-Coquillaud et al. 1993; Owczarek et al. 2004; Perner et al. 2006; Sreenath et al. 
2011). 
 
 
 
 
 
 
 
 
Meanwhile, TMPRSS2-ERG fusions have been detected in approximately 20% of 
HGPIN lesions but not in benign prostate tissue nor prostatic atrophy (PIA). This came to 
reinforce the idea that these rearrangements may be an early event during prostate cancer 
development and that high-grade PIN lesions are a subset of true precursors for TMPRSS2-
Figure 9 – Multiple fusion 
transcript isoforms. Structures 
for TMPRSS2 (red) and ERG 
(blue) are shown. Noncoding and 
coding exons are shown in small 
and large boxes, respectively. 
Transcripts differ in the location of 
the junction between the 5’ partner 
and the ETS gene, as well as the 
included exons (Tomlins et al. 
2009). 
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ERG positive prostate cancer (Cerveira et al. 2006; Perner et al. 2006; Clark et al. 2008a; 
Mosquera et al. 2008). 
 
 
7.2.2. ERG rearrangements as diagnostic & prognostic factors 
 
At the diagnostic level, it is already known that TMPRSS2-ERG fusions produce unique 
chimeric mRNAs and proteins that may allow the development of sensitive detection assays. 
The expression of such fusions appears to be specific of prostate neoplastic cells. Indeed, the 
sensitivity of detection of the fusion transcripts in urine is estimated to be ~ 40% and the 
positive predictive value is ~ 95% (Laxman et al. 2006; Hessels et al. 2007; Laxman et al. 
2008; Salagierski and Schalken 2012). Some groups are combining different biomarkers in 
order to increase the accuracy of PCa detection . These multiplex urine based assays may be 
an important and necessary step to predict prostate cancer malignant potential (Laxman et al. 
2008; Ploussard and de la Taille 2010; Hanash et al. 2011; Salagierski and Schalken 2012). 
However, further testing is needed before routine clinical application. 
Data on the association of ETS fusion genes and patient outcome still remains dubious. 
Several studies suggest that TMPRSS2-ERG rearranged tumors are related to a more 
aggressive phenotype and, consequently, to a worse prognosis (Wang et al. 2006; 
Demichelis et al. 2007; Attard et al. 2008a). Conversely, other results showed no correlation 
between the fusion gene status and patients outcome (Petrovics et al. 2005; Winnes et al. 
2007; Saramäki et al. 2008; Gopalan et al. 2009; Rubio-Briones et al. 2010; Barros-Silva et 
al. 2011). In an attempt to associate clinical data with specific characteristics of TMPRSS2-
ERG gene rearrangements, a multivariate analysis showed that the duplication of TMPRSS2-
ERG fusion in combination with deletion of 5’-ERG (referred to as 2+Edel) was associated 
with a poor clinical outcome when compared with cancers containing only a single copy, 
representing a prognostic independent factor of Gleason score, age and pretreatment PSA 
level (Attard et al. 2008a). Still, assessment of DNA ploidy by flow cytometry led the authors 
to conclude that PCa aggressiveness was actually justified by aneuploidy rather than 
duplication of the gene fusion itself (Attard et al. 2008a; Yoshimoto et al. 2008). 
Additional studies are needed to help solve the discordant prognostic significance of 
gene fusions in PCa progression. 
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7.3. Gene fusions involving other ETS 
 
Meanwhile, other studies have identified fusion events including additional ETS 
transcription factors with outlier expression in prostate cancer samples, namely ETV1 (ETS 
variant 1 gene; 7p21), ETV4 (ETS variant 4 gene; 17q21), ETV5 (ETS variant 5 gene; 3q27) 
and FLI1 (Friend leukemia virus integration 1 gene; 11q24) (Tomlins et al. 2005, 2006; 
Helgeson et al. 2008; Paulo et al. 2012a). 
Further characterization showed that most of these ETS are involved in gene fusions 
with TMPRSS2, but also with other genes. For instance, ETV1 fuses with one of multiple 
additional 5´upstream promoter genes, accounting nine different fusion partners so far. Some 
of them included untranslated regions from a prostate-specific androgen-induced gene 
(SLC45A3/Prostein) and an endogenous retroviral element (HERV-K), both functionally 
analogous to TMPRSS2; a prostate-specific and androgen-downregulated gene (C15orf21) 
and a strongly expressed housekeeping gene (HNRPA2B1) insensitive to androgens    
(Table 3) (Tomlins et al. 2007b; Attard et al. 2008b; Kumar-Sinha et al. 2008; Clark and 
Cooper 2009).  
 
 
7.3.1. ETV4, ETV5 and FLI1 
 
Fusions involving ETV4 and ETV5 have been reported to occur in 5% and ~1% of 
prostate cancers, respectively (Tomlins et al. 2006; Helgeson et al. 2008). 
Hermans and colleagues have identified two novel 5’ fusion partners of ETV4: the KLK2 
and the CANT1 (Table 3), both prostate-specific and androgen-induced genes with important 
unique aspects. The former is a well-established prostate marker that, when fused to ETV4, 
generates an additional ETV4 exon, denoted exon 4a. The later has two alternative first 
exons, but only one is involved in the CANT1-ETV4 fusion transcript. So, these two additional 
fusion genes indicate prostate-specificity and androgen-regulation as evident characteristics 
of ETV4 fusion partners in prostate cancer (Hermans et al. 2008a). The majority of fusion 
genes and transcripts are characterized by the presence of a protein-coding region derived 
largely from the ETS family gene, and in all fusion variants the ETS domain seems to be 
retained. Han et al. (2008) identified a new ETV4 5’ partner gene, DEAD (Asp-Glu-Ala-Asp) 
box polypeptide 5 (DDX5) (Table 3). The three coding exons (103 aminoacids) of this 
ubiquitously androgen-insensitive RNA helicase gene are fused in frame to ETV4 exon 5 in 
one PCa case with ETV4 outlier expression, giving rise to a putative fusion protein (Han et al. 
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2008). On the other hand, ETV5 has been observed to fuse to the two most common 
androgen-induced genes (TMPRSS2 and SLC45A3) (Table 3) (Helgeson et al. 2008). 
Until this year, FLI1, which together with ERG form one subfamily of ETS proteins as 
denoted by genome-wide analysis (Hollenhorst et al. 2007), was speculated to be involved in 
genomic fusions in prostate tumors. Our group was the first to report FLI1 gene as the fifth 
ETS transcription factor involved in fusion genes in prostate cancer. A structural 
rearrangement was found using FISH probes flanking the gene and dual-color, dual fusion 
FISH, RT-PCR and sequencing analyses demonstrated that SLC45A3 was the fusion partner 
(Table 3) (Paulo et al. 2012a). 
 
 
Table 3 – ETS fusion partners in human prostate cancer (adapted from (Clark and Cooper 2009)). 
 
 
Fusion 
partner 
 
Locus 
 
Function of fusion  
partner 
 
Androgen 
Response 
 
Study 
 
ERG     
 
TMPRSS2 
 
21q22 
 
Transmembrane protease 
 
Upregulated 
 
(Tomlins et al. 2005) 
SLC45A3 1q32 Solute carrier protein Upregulated (Han et al. 2008) 
NDRG1 8q24.3 Cytoplasmic protein Upregulated (Pflueger et al. 2009) 
 
ETV1     
 
TMPRSS2 
 
21q22 
 
Transmembrane protease  
 
Upregulated  
 
(Tomlins et al. 2005) 
SLC45A3 1q32 Solute carrier protein  Upregulated  (Tomlins et al. 2007b) 
ACSL3  2q36.1 Acetyl-CoA synthetase Upregulated  (Attard, et al. 2008b) 
HERV-K 22q11.23 Endogenous retrovirus Upregulated (Tomlins et al. 2007b) 
HERV-K17  17p13.1 Endogenous retrovirus  Upregulated  (Tomlins et al. 2007b) 
FOXP1 3p13 Forkhead box P1 Upregulated (Hermans et al. 2008b) 
EST14 14q21.1 Unidentified expressed 
sequence 
Upregulated (Hermans et al. 2008b) 
C15orf21  15q21.1 Unidentified ORF  Downregulated  (Tomlins et al. 2007b) 
HNRPA2B1 7p15 Ribonuclear protein No effect (Tomlins et al. 2007b) 
 
ETV4     
 
TMPRSS2 
 
21q22 
 
Transmembrane protease  
 
Upregulated  
 
(Tomlins et al. 2006) 
KLK2 19q13.33 Kallikrein peptidase Upregulated (Hermans et al. 2008a) 
CANT1 17q25.3 Calcium activated 
nucleotidase 
Upregulated (Hermans et al. 2008a) 
DDX5 17q24.1 RNA helicase No effect (Han et al. 2008) 
INTRODUCTION
      
56 
 
ETV5     
 
TMPRSS2 
 
21q22 
 
Transmembrane protease  
 
Upregulated  
 
(Helgeson et al. 2008) 
SLC45A3 1q32 Solute carrier protein Upregulated (Helgeson et al. 2008) 
 
FLI1     
 
SLC45A3 
 
1q32 
 
Solute carrier protein  
 
Upregulated  
 
(Paulo et al. 2012a) 
 
 
7.3.2. The PEA3 sub-family 
 
ETV1, ETV4 and ETV5 (also called ER81, PEA3/E1AF and ERM, respectively) belong 
to the PEA3 subgroup of the ETS transcription factors family, so named from their close 
homology to mouse pea3, which was the first member to be discovered through its ability to 
bind a motif in the polyomavirus enhancer (Martin et al. 1988; Xin et al. 1992; Monté et al. 
1994; Laudet et al. 1999). These three proteins exhibit high sequence homology within their 
ETS domain, and have conserved regulatory domains (Figure 10) (Bojović and Hassell 
2001). Much interest has been surrounding PEA3 proteins because of their association with 
cancer (Sharrocks 2001; Oikawa and Yamada 2003). In normal adult tissues, these proteins 
are generally expressed at low levels, but in cancer tissues the mRNA and protein levels are 
often up-regulated. PEA3 factors regulate transcription of multiple target genes, such as 
those encoding matrix metalloproteinases (MMP), and have been reported to be associated 
with colon, breast, ovarian and prostate cancer (Launoit et al. 2000; Horiuchi et al. 2003; 
Lynch et al. 2004; Cowden Dahl et al. 2007; Tomlins et al. 2007b). 
 
 
Figure 10 – Scheme of the three human PEA3 ETS transcription factors. Acidic domains are 
highlighted in grey and the ETS DNA-binding domain in black (Oh et al. 2012). 
 
INTRODUCTION
      
57 
7.4. Functional studies of ETS fusion genes in prostate cancer 
 
Our group has recently obtained evidence that ERG and FLI1 have shared and specific 
ETS target genes (Paulo et al. 2012a). On the other hand, some in vitro studies have been 
performed in order to characterize the functional role of different ETS fusion genes in prostate 
cancer, using prostate cancer cell lines. 
 
 
7.4.1. Functional studies of ERG 
 
The VCaP prostate cancer cell line, which harbors the TMPRSS2-ERG fusion gene 
(Korenchuk et al. 2001), has been used as a model to study ERG’s role in the malignant 
transformation of cells. Previous studies have shown that knockdown of ERG resulted in cell 
morphologic alterations and caused inhibition of cell invasion (Tomlins et al. 2007b; Sun et al. 
2008; Tomlins et al. 2008; Wang et al. 2008). However, conflicting results regarding the 
involvement of ERG in cell proliferation have been reported (Tomlins et al. 2007b; Klezovitch 
et al. 2008; Sun et al. 2008; Tomlins et al. 2008). Moreover, exogenous expression of 
TMPRSS2-ERG in prostate cancer cell lines or immortalized benign prostate epithelial cells 
induced invasion, but was unable to increase cellular proliferation or promote anchorage-
independent growth (Mertz et al. 2007; Watson et al. 2010; Rahim et al. 2011). 
 
 
7.4.2. Functional studies of ETV1 
 
Similarly, downregulation of ETV1 in the human prostate adenocarcinoma cell line 
LNCaP, which is positive for the MIPOL1-ETV1 rearrangement (Tomlins et al. 2007b),  
resulted in significant inhibition of invasive properties of these cells, leading to a reduction in 
the expression of matrix metalloproteinases (MMPs), known to be involved in cell invasion 
(Changmeng Cai et al. 2007). On the other hand, ETV1 overexpression in prostate epithelial 
cell lines RWPE and PrEC led to an increase in cells invasiveness in Matrigel assays and 
induced an invasion-associated transcriptional program (Tomlins et al. 2007b; Hermans et al. 
2008b). These studies suggest that ETV1 expression, like ERG expression in the studies 
mentioned above, is sufficient to activate an invasive growth program, but not essential for 
the maintenance of transformation in these cell lines. 
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7.4.3. What about the remaining ETS rearrangements? 
 
Functional studies of ETV4 and ETV5 in cell line models are scarce and non-existent 
for FLI1. A recent report by Hollenhorst et al. (2011) showed that prostate cancer cell line  
PC-3 expresses high levels of ETV4 and that this ETS is necessary for the robust anchorage-
independent growth observed in these cells. Furthermore, silencing of ETV4 also led to a 
decrease in cellular migration and underexpression of genes related to cellular proliferation 
and cell cycle (Hollenhorst et al. 2011b). This has provided the first evidence that 
overexpression of one of the five oncogenic ETS transcription factors is important for the 
transformation program of a prostate cancer cell line. On the other hand, a single study 
showed that ETV5 ectopic overexpression is responsible for inducing invasion in benign 
prostate cell line RWPE through a modified basement membrane assay, but not proliferation 
(Helgeson et al. 2008) and there are no reports unraveling the role of FLI1 gene in prostate 
cancer cells. 
Since there are no prostate cancer cell line models with ETV5 or FLI1 rearrangements, 
we decided to investigate the mechanism and functional role of ETV4 overexpression in 
different cell line models with and without known genomic rearrangements in other ETS 
genes. 
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AIMS 
 
In order to contribute to a better understanding of prostate carcinogenesis, the general 
aim of this work was to study the role of ETV4 on the phenotype of two prostate cancer cell 
lines overexpressing this ETS, namely PC-3 and MDA-PCa-2b the latter having also an ETV1 
rearrangement. 
Therefore, the following specific research lines were addressed: 
 
 To verify ETV4 knockdown at the mRNA and protein levels by real-time RT-PCR 
and immunoblotting in the stably silenced PC-3 and MDA-PCa-2b cells; 
 
 To determine the phenotypic impacts caused by in vitro silencing of ETV4 gene 
in these prostate cancer cell line models; 
 
 To evaluate the impact of ETV4 silencing on global gene expression signature 
of PC-3 and MDA-PCa-2b derived cells using a microarray-based gene 
expression profiling approach. This may provide novel insight into the molecular 
mechanisms mediating prostate cancer progression. 
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MATERIALS AND METHODS 
 
In this chapter, the different methods used will be described in detail, as well as the 
main principles of cell culture assays.  
 
1. Cell Lines and Cell Culture 
 
Human prostate cancer cell lines were used for in vitro experiments, namely PC-3 and 
MDA-PCa-2b cell lines, the former being negative for known ETS rearrangements and the 
latter being positive for the MIPOL1-ETV1 rearrangement (Tomlins et al. 2007b). The two 
cells are known to overexpress our ETS of interest – ETV4 (Table 4). 
Although both were derived from bone metastasis of prostate cancer patients, they 
have distinct features along with different phenotypes: PC-3 is a hormone-refractory, PSA 
negative cell line, whereas MDA-PCa-2b cells have retained PSA expression and androgen 
sensitivity (Kaighn et al. 1979; Navone et al. 1997). 
PC-3 cells were acquired from the German Resource Centre for Biological Material 
(DSMZ, Braunschweig, Germany), and MDA-PCa-2b cells were kindly provided by Prof. 
Ragnhild A. Lothe from the Department of Cancer Prevention at the Institute for Cancer 
Research, Oslo University Hospital, Norway. 
The next table (Table 4) summarizes some relevant characteristics of the cell lines 
used. 
 
Table 4 – Overview of the relevant characteristics of prostatic cell lines. 
 
 
Cell line 
 
Origin 
 
Properties 
 
ETV4 status 
 
Other ETS 
status 
 
References 
 
PC-3 
 
 
Prostate 
adenocarcinoma 
 
Adherent 
High division 
rate 
 
Overexpressed 
 
ETV1 
overexpressed 
 
(Kaighn et al. 
1979; 
Tomlins et al. 
2007b; 
Hollenhorst, 
et al. 2011b) 
 
 
MDA-
PCa-2b 
 
Prostate 
adenocarcinoma 
 
Adherent 
Low division 
rate 
 
Overexpressed 
 
ETV1 
overexpressed 
 
(Navone et 
al. 1997; 
Tomlins et al. 
2007b) 
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PC-3-derived cell populations were grown in F-12 medium (GIBCO®, Invitrogen, 
Carlsbad, CA) supplemented with 10% Fetal Bovine Serum (FBS) (GIBCO®, Invitrogen, 
Carlsbad, CA) and 1% Penicillin/Streptomycin (GIBCO®, Invitrogen, Carlsbad, CA) and MDA-
PCa-2b-derived cell populations were cultured in BRFF-HPC1 medium (Gentaur, Brussels) 
with 20% FBS and 1% Penicillin/Streptomycin. All cultures were grown under standard 
conditions (37ºC, 5% CO2). 
All prostate cell lines were routinely tested for Mycoplasma spp. contamination (PCR 
Mycoplasma Detection Set, Clontech Laboratories). 
 
 
2. In Vitro Silencing of ETV4 Expression 
 
In the past few years, outstanding developments in RNA interference (RNAi)-based 
methodologies have been made in an attempt to mediate the down-regulation of gene 
expression, in order to study gene function in mammalian cells (Bantounas et al. 2004). 
RNAi-mediated knockdown or post-transcriptional down-regulation of a gene of interest is 
achieved either by synthetic small interfering RNAs (siRNAs) or by expression of short hairpin 
RNAs (shRNAs). Contrarily to siRNAs, which induce only temporary (48-72h) gene down-
regulation, shRNAs are delivered to mammalian cells by viral or non-viral vectors resulting in 
long-term silencing of the target gene (Aagaard et al. 2007). 
Stable silencing of ETV4 in PC3 and MDA-PCa-2b cells was previously accomplished 
by our group using a retroviral gene transfer technique (Paulo et al. 2012b) (Figure 11). 
Briefly, to generate constructs for stable silencing of ETV4, two shRNA sequences (starting at 
664bp and 940bp of the translation start-site) were selected and designed using the RNAi 
Target Sequence Selector and the shRNA Sequence Designer, respectively. shETV4 
sequences were cloned into the pSIREN-Retro-Q vector (Clontech), which contained a 
puromycin resistance gene and a packaging signal. A negative control vector carrying a non-
targeting sequence (pSIREN-shNeg) was also generated (Protocol No. PT3132-1, Version 
No. PR631543). After transfection into a packaging cell line to produce retroviral-shRNA-
containing particles, viral medium was harvested and used to infect PC-3 and MDA-PCa-2b 
cells. Stably silenced cell populations (PC-3 shNeg, PC-3 shETV4664, MDA-PCa-2b shNeg 
and MDA-PCa-2b shETV4664) were obtained by puromycin selective pressure. Two 
independent, low ETV4 expression clones were isolated from each cell line using the serial 
dilutions technique and expanded for further analyses. All these established stable cell lines 
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Packaging cell 
were maintained in growth medium containing 1g/mL puromycin (Clontech Laboratories). To 
facilitate results presentation and following discussion, these downregulated clones will be 
referred to as PC3-C1/MDA-PCa-2b-C1 (clone 1) and PC3-C2/MDA-PCa-2b-C2 (clone 2), 
respectively. Cells transfected with vector only will be pointed as shNeg. 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11 – Scheme that summarizes the knockdown of ETS chimeric genes by RNA 
interference. Synthetic oligonucleotides containing the target sequences designed to produce shRNA 
structures specific for ETV4 were inserted into the BamHI/EcoRI sites of the RNAi-Ready pSIREN-
Retro-Q vector and transfected into a packaging cell line. Effectively transfected cells were grown 
under puromycin selective pressure for stable retroviral production. The retroviral containing medium 
was used to infect PC-3 and MDA-PCa-2b cells, generating stable shETV4 populations that were 
grown in the presence of puromycin. Clonal populations were isolated and two independent clones with 
silenced ETV4 expression were expanded. 
Insertion of shRNA sequences into the vector 
Integration 
Transcription 
Packaging 
Budding of infectious but replication-incompetent virus 
Cells grown under puromycin 
selective pressure 
Virus harvesting 
Infection of target 
prostate cancer cells 
Effectively transduced cells grown under 
puromycin selective pressure (1g/mL) 
Isolation of independent clones 
Evaluation of ETV4 silencing by quantitative real-time 
RT-PCR and immunoblotting 
Transfection into a 
packaging cell line 
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3. Phenotypic Assays 
 
The study of human cancer-derived cell lines allowed us to better understand cancer 
biology and the mechanisms of drug sensitivity and resistance. Experimental in vitro models 
are important for reconstructing molecular events associated with prostatic carcinogenesis, 
due to their capacity of mimicking the phenotypic and genotypic changes often observed in 
clinical human prostate cancer patients (Borrell 2010). 
Characterization of the functional role of ETS fusion genes in prostate cancer requires 
several in vitro and in vivo studies, including phenotypic assays. 
 
 
3.1. Proliferation assay – MTT 
 
Rapid and accurate assessment of viable 
cell number and cell proliferation is an important 
requirement in many experimental situations. The 
colorimetric assay using 3-(4, 5-dimethylthiazollyl-
2)- 2,5-diphenyltetrazolium bromide (MTT) was 
initially proposed by Mosmann as a quantitative 
measure of mammalian cell survival and cell 
proliferation (Mosmann 1983).  
This assay is dependent on the reduction of 
the tetrazolium salt MTT by the action of 
dehydrogenase enzymes of viable cells to form 
purple formazan crystals, which can be dissolved 
in acidic alcohol solution before making a 
spectrophotometric measurement (Figure 12). 
The assay is based on the principle that the 
amount of formazan produced is directly 
proportional to the number of live cells (Mosmann 
1983; Peck 1985). 
 
                                  Figure 12 – Measurement of metabolic activity using the tetrazolium 
 salt MTT (adapted from (Mannheim 1998)). 
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Briefly, PC-3-derived cells were plated in 96-well plates at a density of 5x103 cells per 
well and incubated at normal conditions for 24, 48, 72 and 96hr. At each time point, the 
medium was removed and cells were incubated with 10L of MTT solution (5mg/mL, Sigma) 
for 2hr at normal growth conditions. Once the crystals were formed, MTT was removed and 
50L of dimethyl sulfoxide (DMSO, Merck) were added to each well to dissolve formazan. 
The optical density was measured using a microplate reader (BMG Labtech) at a wavelength 
of 540nm with background correction at 630nm. For MDA-PCa-2b-derived cells (shNeg, 
shETV4-C1 and shETV4-C2), the cell density used was 3x104 cells per well and the selected 
MTT incubation time was 30 min. Data was expressed as a ratio of the results obtained with 
each clone and the scramble control, from three independent experiments, each including 
nine wells per condition. Analyses were performed using the Student’s t test and the data was 
considered statistically different when calculated p values were inferior to 0.05. 
 
 
3.2. Cell apoptosis assay 
 
Apoptosis is described as an orchestrated collapse of the cell, which is characterised by 
membrane blebbing, cell shrinkage, chromatin condensation, and fragmentation of DNA. 
These observations were made by Kerr et al. as early as 1972, but their relevance was 
underestimated for years (Kerr et al. 1972). 
Nowadays, however, dysfunctions in the regulation of cell fate are known to be 
implicated in a wide range of diseases such as cancer, where the balance between 
proliferation and programmed cell death is compromised (Fulda et al. 2010). 
For apoptosis evaluation, the APOPercentageTM assay kit was used (Biocolor, 
Newtownabbey, Northern Ireland). In order to explain its mode of action, a brief and closer 
examination of the mammalian cell membrane will be required. 
The fluid mosaic model of membrane structure, proposed by Singer and Nicolson in 
1972, describes the membrane as being composed of a phospholipid bilayer with a diverse 
group of inserted proteins and cholesterol (Singer and Nicolson 1972). The membrane 
contains four major phospholipids (phosphatidylcholine, phosphatidylethanolamine, 
phosphatidylserine and sphingomyelin), which are asymmetrically distributed between two 
halves of the membrane bilayer. The outer leaflet of the lipid membrane consists mainly of 
phosphatidylcholine and sphingomyelin, whereas phosphatidylethanolamine and 
phosphatidylserine are the predominant phospholipids of the inner leaflet. To ensure normal 
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transmembrane functions and exchange of molecules between the cytoplasm and the 
extracellular matrix, the action of flippases is needed. These enzymes are known to catalyse 
the active transport of aminophospholipids from the outer to the inner monolayer (Sprong et 
al. 2001). 
An increase in intracellular Ca2+ due to cell activation, cell injury or apoptosis usually 
leads to a rapid bidirectional movement of the plasma membrane between leaflets, the so 
called flip-flop mechanism. During this process, flippase is overwhelmed by the action of 
another enzyme, named floppase, resulting in surface exposure of phosphatidylserine and 
phosphatidylethanolamine (Zhou et al. 1997).  
The APOPercentageTM Apoptosis Assay, used in this experiment, is a detection and 
measurement system that monitors the occurrence of apoptosis in mammalian cells during in 
vitro culture. This assay uses a purple-red dye that is selectively imported by apoptotic 
committed cells. The uptake of the dye is uni-directional, leading to its accumulation within 
the cell (Figure 13). It can also be released into solution and the concentration measured 
using a microplate colorimeter. 
 
Briefly, PC-3-derived and MDA-PCa-2b-derived cells were seeded in 96-well plates at a 
density of 1x104 and 3x104 cells, respectively, and incubated at normal growth conditions for 
48, 72 and 96hr. On the day before each time point, the medium from three wells was 
removed and 10mM of hydrogen peroxide were added, in order to be used as positive 
apoptotic inducer controls. For the apoptotic measurement, 100L of fresh culture medium or 
hydrogen peroxide, both containing 5L of APOPercentage dye (1:20 in solvent), were added 
to the centre of the test and control wells, respectively. After 2hr of incubation, the dye 
mixture was removed and cells were gently washed twice with 200L of PBS to remove 
unbound dye. Representative pictures were collected under an inverted microscope (100x 
magnification). To release the dye within labelled cells into solution, 100L of 
APOPercentage dye release reagent were added to each well and the absorbance was 
measured at 550nm using a microplate colorimeter (BMG Labtech).  
Three independent experiments were performed, using duplicate wells for each 
condition, and results are expressed as a normalized ratio of each clone and the scramble 
control. A p value inferior to 0.05 was considered statistically significant. 
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Figure 13 – Asymmetric phospholipid composition of a transformed mammalian cell. The 
phospholipid bilayer structure is essential for the normal functions of a viable cell. Maintaining its 
composition is an energy dependent process involving the activity of enzymes, termed flippases. In 
apoptotic committed cells, flippase regulation is inactivated by floppase. The transfer of 
phosphatidylserine to the outside of the membrane allows the transport of the APOPercentage dye and 
its accumulation. As the cell shrinks in volume, during the apoptotic process, the cell dye content 
becomes more concentrated (adapted from the Biocolor’s protocol; www.biocolor.co.uk). 
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3.3. Soft-agar assay for colony formation 
 
Traditionally, the soft agar colony formation assay is a common method used to monitor 
anchorage-independent growth, which measures the ability of a single cell to grow 
unattached to a surface. The process by which these phenotypic changes occur is assumed 
to be closely related to the process of in vivo carcinogenesis, and it is considered one of the 
most accurate in vitro assays for detecting malignant transformation of cells. 
 
For this experiment, 1.2% agarose were melt in the microwave for short periods of time 
(25-30 seconds), and cooled to 40ºC in a water bath. A solution of F-12 and BRFF-HPC1 
media, supplemented with 20 and 40% FBS and antibiotics respectively, was prepared. Equal 
volumes of medium and agarose were mixed in order to obtain a 0.6% agarose + F-12/BRFF-
HPC1 + additives solution. Then, 2mL were plated in each well of a 6-well plate and were left 
to set for 20 min. 
A second layer of agarose was prepared. For that, 0.4% agarose diluted in sterile water 
were melt in a microwave and also cooled to 40ºC. While cooling down, cells were trypsinized 
and counted. Equal volumes of medium and agarose were mixed giving a 0.2% agarose +   
F-12/BRFF-HPC1 solution and a density of 1x105 and 5x104 PC-3 and MDA-PCa-2b-derived 
cells, respectively, were suspended in this agarose mix. 
One millilitre of this solution was added to each two replicate wells and cells were 
incubated at normal growth conditions. Each well was allowed to solidify and was 
subsequently covered with 1mL of the corresponding culture medium, which was changed 
every 3 days to prevent agarose dehydration and an unlimited nutrient source. Colonies 
formed after two weeks were counted in four optical fields of each well using an inverted 
microscope at 100x magnification. 
The mean values (±SD) of PC-3 and MDA-PCa-2b-derived cells were obtained from 
duplicate wells at the end of the time-point. Results are representative of three independent 
experiments and are shown as a ratio between the number of colonies formed and the 
number of cells seeded. A p value inferior to 0.05 was considered statistically different. 
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3.4. Invasion assay 
 
Cell invasion was evaluated using the Oris TM Cell Invasion & Detection Assay kit 
(Platypus Technologies, LLC.), according to the manufacturer’s instructions. 
 
This system, used only with adherent cell cultures, is designed to detect cellular 
invasion in vitro within a 3-dimensional extracellular matrix comprised of a basement 
membrane extract (BME) of the Murine Engelbreth-Holm-Swarm tumor. It is formatted for a 
96-well plate and utilizes Oris TM Cell Seeding Stoppers which are capable of restricting cell 
seeding to the outer annular regions of the wells. By removing them, unseeded region in the 
centre of each well will be revealed, i.e., the detection zone into which the seeded cells may 
then invade. A Oris TM Detection Mask is applied in the end of the experiment to the plate 
bottom; its main purpose is to restrict visualization to the detection area, and hence allowing 
only invading cells to be observed (Figure 14). 
Quantification is performed by using the Calcein AM Staining Reagent, and the 
fluorescence is measured in a microplate reader. 
 
 
 
Figure 14 – Schematic of Oris 
TM
 Cell Invasion & Detection Assay (adapted from Platypus Tech 
protocol; www.platypustech.com). 
 
For this assay, the Oris TM BME Stock Reagent was mixed with serum-free medium to 
obtain a BME Coating Solution (3.5mg/mL) and 100L of this mixture were added to each 
well of the 96-well plate. The BME Coating Solution was immediately removed and the plate 
incubated for 30 min in a humidified chamber at 37ºC with 5% CO2. Then, the Oris 
TM Cell 
Seeding Stoppers were vertically inserted and the underside of the populated plate was 
visually inspected to ensure complete sealing against the bottom of the plate. 
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PC-3-derived and MDA-PCa-2b-derived cells were seeded at a cell density of 1.5x104 
and 1x105 in the test wells, respectively, whereas a density of 5x103 and 1x104 was platted in 
the control wells. A positive control was included, namely the TPC-1 invasive cell line – which 
is derived from the urothelium of a papillary carcinoma in the left renal pelvis (Chang et al. 
1995). The cell seeding concentration used for this cell line was 1x104 cells in the test wells 
and 500 cells/well in the controls. 
Once prepared, 100µL of the cell suspensions were pipetted into each well through one 
of the side ports of the Oris TM Cell Seeding Stopper. The seeded plate was incubated at 
37ºC for 24hr (PC-3) and 48hr (MDA-PCa-2b) to allow cell attachment, after which the 
stoppers were removed from the test wells. Medium was then pulled out and the wells were 
gently washed with sterile PBS to remove any unattached cells. The Oris TM BME Stock 
Reagent was used to prepare a second layer of BME, diluted in serum-free medium, at a 
concentration of 12mg/mL. Fourty microlliters of this solution were added to each test well to 
create a 3-D BME overlay. The plate was incubated for 60 min to allow polymerization, and 
then 100L of serum-free cell culture medium were added on top of the 3-D BME overlay. 
The medium was changed every 72hr.  
In order to observe cell invasion, the plate was incubated at 37ºC with 5% CO2 for 8 
days or when 2/3 of the cells were already observed in the detection area. When performing 
an end-point analysis, stoppers left in the control wells to represent t=0 reference were 
removed and overlaid with 40L of BME (12mg/mL). After polymerization, cells were ready to 
be stained with calcein reagent. A working dilution of calcein was prepared combining 5L of 
Calcein AM (1mg/mL in DMSO) with 10mL of 1x PBS and protected from light until ready to 
use. After carefully removing the medium, wells were washed with PBS and overlaid with 
100L of the diluted Calcein AM solution. After 60min of incubation at 37ºC, the Oris TM 
Detection Mask was attached to the plate and measurements were made in a microplate 
reader using an excitation/emission filters at 485/528nm. Results were expressed as a ratio 
of the data obtained with each clone and the scramble control, from two independent 
experiments. A p value of less than 0.05 was considered as statistically significant. 
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4. Molecular Biology 
 
4.1. RNA and protein extraction 
 
RNA and protein were extracted from sub-confluent PC-3- and MDA-PCa-2b-derived 
cell lines using the Illustra TriplePrep kit (GE Healthcare, Life Sciences, Cleveland, USA), 
according to the manufacturer’s recommendations. The RNA concentration and purity were 
measured in a NanoDrop ND-1000 spectrophotometer (NanoDrop Technologies, USA). 
Protein concentration was determined by the Pierce® BCA Protein Assay (Thermo Fisher 
Scientific, Rockford, USA) following the manufacturer’s instructions. This method relies on the 
binding of a reagent containing bicinchoninic acid (BCA) to proteins, giving rise to a purple-
colored reaction product. Thus, protein quantification can be estimated by determining the 
amount of this water-soluble complex, which is achieved by measuring the absorbance of the 
solution at 562nm. Accordingly, protein concentrations were determined based on a standard 
curve built with a series of dilutions of known concentration of bovine serum albumin (BSA) 
(2,000g/mL; 1,000g/mL; 500g/mL; 250g/mL; 125g/mL; 0g/mL). For the BCA reaction, 
25L of each standard or unknown sample were mixed with 200L of the BCA working 
solution and incubated for 30 min at 37ºC.  
 
 
4.2. cDNA synthesis 
 
Double-stranded cDNA was synthesized from 1g of total RNA using the RevertAid TM 
H Minus First Strand cDNA Synthesis Kit (Fermentas, Ontario, USA) in the presence of 
Oligo(dT) primers.  
In brief, RNA samples were incubated at 70ºC for 5 min to allow denaturation to occur. 
Then, the reaction was cooled on ice and the subsequent components were added:             
5x Reaction Buffer, 20U/L RiboLock TM RNase Inhibitor and 10mM dNTP mix. The mixture 
was incubated at 37ºC for 5 min. Finally, 200U/L RevertAid TM H Minus M-MuLV Reverse 
Transcriptase were added and reacted at 42ºC for 60 min, followed by inactivation at 70ºC for 
10 min. The newly synthesized cDNA was stored at -20ºC. 
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4.3. Quantitative reverse-transcription PCR (qRT-PCR) 
 
To quantify the relative expression levels of the ETV4 transcription factor, quantitative 
real-time PCR was performed. The expression of ETV1 in these samples was also evaluated.  
Primers and probes were either designed for the genes of interest (ETV4) using the 
software Primer Express and acquired from Metabion (Martinsried, Germany) or acquired as 
pre-developed TaqMan® Gene Expression Assays from Applied Biosystems 
(LifeTechnologies, Foster City, CA) (ETV1). The beta-glucuronidase (GUSB) housekeeping 
gene was used as an endogenous control for normalization of the expression levels      
(Table 5). 
Reactions were optimized to run in 96-well plates on the Applied Biosystems 7500 
Real-time PCR system (Applied Biosystems, CA, USA). Briefly, each well included our cDNA 
samples, 7.5M of each primer or 20x TaqMan® Gene Expression Assay, 2x TaqMan® 
Universal PCR Master Mix and DEPC-treated water (deionized, nuclease-free water) (MP 
Biomedicals, LLC, USA) for a final volume of 25L. Triplicate reactions were run for all cDNA 
samples and multiple negative controls (DEPC-treated water) were included in each plate. 
The cycling conditions for all genes were the following: 50ºC for 2 min, 95ºC for 10 min and 
45 cycles at 95ºC for 15 sec and 60ºC for 1 min. 
 
Table 5 – Assay ID or sequence of the primers and probes used.  
 
 
Assay 
 
Assay/Primer name 
 
Assay ID/Primer sequence 5’-3’ 
 
qRT-PCR 
 
ETV1 
 
Hs00951941_m1 
 
 
qRT-PCR 
 
 
ETV4 
 
PF – GGAATGGAGTTCAAGCTCATTGA 
PR – TAATTCATGGCTGGCCGGTTCT 
PB - CCAGAGCCTGGCGACCTCCTCAG 
 
qRT-PCR 
 
GUSB 
 
4333767F 
 
Abbreviations: PF – Primer Forward; PR – Primer Reverse; PB - Probe 
 
Results were analyzed using the Sequence Detector Software version 2.0.5 (Applied 
Biosystems, Foster City, CA, USA). The relative expression values of each gene were 
quantified on the basis of the comparative CT method, measured against an internal standard 
curve. The following equation was used: 2-ΔCT = CT gene of interest – CT internal control 
(Schmittgen and Livak 2008), where the CT is defined as the PCR cycle that indicates the 
fractional cycle number at which the amount of amplified target reaches a fixed threshold. 
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Ideally, and as observed for our genes, it should be above the baseline and within the 
exponential phase of the amplification curve. Using a standard curve built with a series of 
cDNA dilutions from a sample that expresses high levels of the gene to be analyzed, both the 
efficiency of the genes of interest and the efficiency of the endogenous control (GUSB) was 
close to 1, thus validating the use of the comparative CT method (Schmittgen and Livak 
2008). 
 
 
4.4. Fluorescent in situ hybridization 
 
FISH was used to evaluate the possibility of a genomic rearrangement involving the 
ETV4 transcription factor in PC-3 and MDA-PCa-2b-derived cells. Bacterial artificial 
chromosomes (BACs) were obtained from the BACPAC Resource Center (Oakland, CA) and 
the integrity and correct localization of all probes was verified on normal human metaphases. 
For the detection of ETV4 rearrangements, the following BAC clones were used as probes: 
RP11-259G18 (5’ to ETV4; red probe) and RP11-831F13 (3’ to ETV4; green probe), whereas 
RP11-941F13 (5’ to ETV1; red probe) and RP11-790J2 (3’ to ETV1; green probe) were used 
to target the ETV1 gene. BAC DNA was isolated using the NucleoSpin® Plasmid QuickPure 
kit (Macherey-Nagel, Germany), and probes were synthesized using the Nick-Translation 
DNA Labeling System (Cat. No. ENZ-42910; Enzo® Life Sciences, USA). 
 
 
4.5. Immunoblotting analysis 
 
Protein extracts were separated on a 10% SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) (Figure 15). Briefly, 40g of protein were mixed with 5x loading buffer (0.5M 
Tris-HCl pH 6.8, 2% SDS, 10% glycerol and 0.05% bromophenol blue) (5:1) and denatured 
for 5 min at 95ºC. Samples were loaded in the gel together with a Dual-Color standard marker 
(Bio-Rad, Munich, Germany) and run at 120V/cm. 
In order to make the proteins accessible to antibody detection, they were transfered 
from the gel to a 0.1m nitrocellulose membrane (Sigma-Aldrich, Steinheim, Germany). For 
the electroblotting, sponges and filter papers were pre-wet in 1x Tris-Glycine buffer with 20% 
methanol and the sandwich was assembled. The transfer was run for 1hr at 50V/cm and the 
membrane was then blocked for 3hr in blocking solution (5% non-fat dry-milk in TBS-0.1% 
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Tween 20) to reduce non-specific binding. The primary antibody, diluted in blocking solution 
(Table 6), was incubated with the membrane overnight at 4ºC under agitation. The 
membrane was then washed three times in TBS-0.1% Tween 20 for 5 min/each and 
incubated for 1hr at room temperature with a secondary antibody linked to a reporter enzyme 
– the horseradish peroxidase (HRP) – and diluted in blocking solution (Table 6). 
 
 
Table 6 – Antibodies used in western blot and respective work dilutions. 
 
 
 
 
Name 
 
Dilution 
 
Supplier  
 
 
Primary Antibody 
 
anti-ETV4 
 
1:500 
 
Abnova 
 
anti-ETV1 
 
1:500 
 
Sigma-Aldrich 
 
anti-β-actin 
 
1:8000 
 
Santa Cruz 
 
Secondary Antibody 
 
goat anti-mouse IgG – HRP  
 
1:2500 
 
Santa Cruz 
 
The membrane was again washed three times with TBS-0.1% Tween 20 and then 
subjected to chemiluminescence detection using the Immun-Star TM WesternC TM kit (Bio-
Rad, Germany). The specific protein bands were visualized by autoradiography. 
 
 
 
Figure 15 – Western blot. The technique depends on the reaction of an antibody with a protein that is 
immobilized on a nitrocellulose membrane. The gel and membrane are placed between sheets of 
absorbent paper in a blotting tank, where proteins will be transferred by electrical current. The 
membrane is then incubated with specific antibodies, and detection is performed by autoradiography 
(www.virology.ws). 
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4.6. Analysis of human PCa cell lines gene expression profile 
 
To identify ETV4 target genes that might be contributing to the phenotypic changes 
observed after ETV4 silencing in PC-3 and MDA-PCa-2b cells, the gene expression profiles 
of the different cell populations were measured by microarray analyses. The GeneChip 
Human Exon 1.0 ST array (17000 genes included) was used to assess whole-transcriptome 
expression levels. The shNeg controls and the two independent shETV4 clones derived from 
PC-3 and MDA-PCa-2b cell lines were compared and the expression profile of each cell 
population was obtained after background correction and normalization in the Affymetrix 
Expression Console v1.1 software, using the Robust Multichip Average (RMA) algorithm. To 
look for candidate ETV4 target genes we selected those that a) showed to be up-regulated or 
down-regulated at least 1.5-fold in both shETV4 clones derived from one cell line comparing 
with the respective shNeg control, and b) showed this differential expression profile in the two 
cell line models. 
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RESULTS 
 
1. ETS Expression Pattern in Prostate Cancer Cell Lines 
 
The ETS expression profile of five different prostate cell lines was previously assessed 
by our group using pre-designed primers and probes in a mRNA quantitative analysis. As 
illustrated in Figure 16, the VCaP and LNCaP cells overexpress specifically ERG and ETV1 
mRNA, respectively, representing two hypothetically suitable cell models to study either one 
of the ETS. On the other hand, two of the five cell lines showed aberrant levels of ETV4. The 
PC-3 cells demonstrated highly increased levels of ETV4 and moderate levels of ETV1, 
whereas the MDA-PCa-2b cell line exhibited ETV1 and ETV4 co-overexpression. Finally, the 
PNT2 benign cell line showed no ERG expression and ETV1/4 baseline levels (Figure 16). 
 
 
 
Figure 16 – Profile of ETS expression in five different prostate cancer cell lines. Quantitative 
analysis of ERG, ETV1 and ETV4 expression in LNCaP, VCaP, MDA-PCa-2b, PC-3 and PNT2 cells. 
According to the ETV4 expression levels, PC-3 and MDA-PCa-2b cells were chosen to 
pursue our studies and functional assays on the role of this gene in prostate carcinogenesis, 
since they presented a clearly accentuated outlier expression. 
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2. ETV4 Rearrangement Status 
 
Before addressing each of the aims proposed on this thesis, FISH validation was 
performed on PC-3 and MDA-PCa-2b cell lines in an attempt to find an explanation for the 
observed ETV4 outlier expression. A break-apart probe strategy flanking the 5’ and 3’ regions 
of the gene was used (Figure 17A). The analysis of chromosome 17 did not indicate a 
chromosomal rearrangement typical of a fusion gene involving ETV4. Instead, PC-3 cells 
showed three copies of the ETV4 gene with no apparent rearrangement and two red signals 
representing the 5’ region of ETV4 on two identical marker chromosomes                     
(Figure 17B and C). As for the MDA-PCa-2b cell line, two distinct cell populations were 
identified: one showing two normal co-localizing signals at the ETV4 locus (Figure 18A) and 
another with two extra pairs of normal signals (presumably a tetraploid population resulting 
from doubling of the former – data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B C 
Figure 17 – FISH analysis of the PC-3 cell line. BAC clones targeting 5’- and 3’-ETV4, labelled red 
and green, respectively, were used for detection of a possible genomic rearrangement. (A) Schematic 
representation of BAC probes flanking ETV4 gene. (B) PC-3 cells displaying one extra normal copy of 
chr 17 and two additional copies of the 5’ region of the gene in marker chromosomes. (C) PC-3 
interphase nucleus showing the corresponding chromosomal alterations as seen in the metaphases. 
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Although no ETV4 rearrangement was found in the MDA-PCa-2b cell line, it is known 
that it has a genomic rearrangement involving the ETV1 gene (7p21.2) that explains its 
overexpression (Tomlins et al. 2007b). Through FISH analysis, we were able to confirm the 
presence of this chromosomal alteration (Figure 18B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18 – FISH analyses for ETV4 and ETV1 in MDA-PCa-2b cell line. (A) MDA-PCa-2b cells 
showing normal copies of chromosome 17. (B) BAC clones targeting 5’-ETV1 (RP11-941F13) and 3’-
ETV1 (RP11-790J2), labelled red and green, respectively, show a normal co-localized signal and an 
abnormal split signal representing an ETV1 rearrangement. 
 
 
3. ETV4 Downregulation by shRNA 
 
To explore the role of ETV4 in prostate cancer, we established two independent 
downregulated clones stably expressing shRNAs directed against ETV4 for distinct prostate 
cancer cell lines, namely PC-3 and MDA-PCa-2b derived cells (C1 and C2), along with one 
scramble control (shNeg). ETV4 silencing was confirmed by quantitative RT-PCR        
(Figure 19). As shown in Figures 19A and 19B, ETV4 shRNA efficiently decreased ETV4 
expression at the mRNA level by more than 80% to 90% in PC-3 derived cells, and 70% to 
90% in MDA-PCa-2b derived cells, respectively, as compared to the scramble control 
(shNeg). 
 
A B 
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Figure 19 – ETV4 knockdown by shRNA evaluated through quantitative analysis. (A) qRT-PCR 
analysis of ETV4 mRNA expression in PC-3 derived cells after ETV4 silencing and comparison to the 
shNeg control. (B) Quantification analysis of ETV4 mRNA by qRT-PCR in MDA-PCa-2b derived cells 
and the shNeg control after ETV4 silencing. Student’s t test was applied to evaluate differences in the 
expression data obtained. P ≤ 0.05 was considered statistically significant. Bars represent standard 
deviation. 
 
 
One of the prostate cancer cell lines – MDA-PCa-2b – was previously described to 
express ETV1 (Tomlins et al. 2007b), which belongs to the same subfamily of ETS 
transcription factors as ETV4. Thus, in order to evaluate its status in ETV4-depleted cells, 
ETV1 expression was determined by quantitative RT-PCR (Figure 20). 
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PC-3 derived cells (C1 and C2) showed an increase of ETV1 mRNA levels when ETV4 
was silenced (Figure 20A), whereas MDA-PCa-2b clone cells had similar mRNA levels of 
ETV1 as compared to the shNeg control (Figure 20B). These data indicate that loss of ETV4 
significantly alters ETV1 expression in PC-3 derived cells, but shows no relevant effect in 
MDA-PCa-2b cell line. 
  
 
 
 
 
 
Figure 20 – ETV1 expression in shETV4 prostate cancer cell lines by qRT-PCR. (A) ETV1 mRNA 
expression in shETV4 PC-3 derived cells, showing a significantly increased expression after ETV4 
silencing. (B) Quantification of ETV1 mRNA by qRT-PCR in MDA-PCa-2b derived cells after ETV4 
silencing. These cells show no differences in the expression of ETV1. Student’s t test was applied to 
evaluate differences in the expression data obtained. P ≤ 0.05 was considered statistically significant. 
Bars represent standard deviation. 
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Finally, the confirmation of ETV4 silencing and ETV1 status at the protein level was 
evaluated by western blot (Figure 21). A significant reduction in the amount of ETV4 protein 
was observed in PC-3 derived cells (C1 and C2), and MDA-PCa-2b-C1 and C2 clones when 
compared to the respective shNeg control. As for ETV1, there was no significant difference in 
the levels of protein, despite the results previously obtained by qRT-PCR showing variations 
at the mRNA level. The housekeeping gene β-actin was used as a loading control between 
the diverse samples. 
 
 
Figure 21 – Confirmation of ETV4 knockdown in PC-3 and MDA-PCa-2b derived cells at the 
protein level by western blot analysis. Both prostate cancer cell lines showed a well marked 
decrease of ETV4 protein in the stably silenced clones (C1 and C2) as compared to the scramble 
control (shNeg). ETV1 protein levels were maintained constant along the distinct samples. The 
housekeeping gene – β-actin – was used as a loading control and was kept homogeneous in all 
samples. The molecular weight of the three detected proteins – ETV4, β-actin, ETV1 – is 55kDa, 
42kDa and 55kDa, respectively. kDa (kilodaltons). 
 
 
4. Functional Relevance of ETV4 
 
Next, in order to gain insight into the oncogenic activity of ETV4, we focused on 
investigating its biological functions in the prostate cancer cell lines stably silenced for this 
ETS by performing different phenotypic assays and gene expression analysis (proliferation, 
apoptosis, colony formation, invasion and gene expression profile). 
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4.1. Cell proliferation 
 
We determined the possible effect of sustained ETV4 knockdown on PCa cell growth in 
vitro. PC-3 ETV4-depleted clones did not significantly alter their growth rate when compared 
to the PC-3 shNeg, after evaluation by the MTT assay (Figure 22A). The same was observed 
for MDA-PCa-2b-C1 and C2 cells (Figure 22B).  
These data showed that ETV4 silencing has no apparent growth inhibitory effects on 
PCa tumor growth in vitro. 
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Figure 22 – Quantification of cell proliferation during 4 days in culture. (A) Quantification of 
metabolically active cells by the MTT assay in PC-3-C1 and C2 clones and shNeg. (B) Quantification 
by the MTT assay of MDA-PCa-2b derived cells and the shNeg control. Student’s t test was applied to 
evaluate differences in the data obtained. Bars represent standard deviation. 
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4.2. Cell apoptosis 
 
To assess whether ETV4 silencing induced cell death through apoptosis, we used the 
APOPercentage TM assay kit. Qualitative and quantitative evaluation was performed on PC-3 
and MDA-PCa-2b depleted cells and respective controls.  
Images from Figure 23A show increased apoptotic rate in PC-3 clones, which is 
illustrated by the uptake of purple-red dye, when compared to the control cells. Positive 
controls, treated with hydrogen peroxide, were used to confirm the assay’s practicability 
(Figure 23A). We also performed quantitative analysis by measuring the concentration of the 
dye in a microplate reader. Although results were not statistically significant, PC-3 silenced 
cells showed a tendency for higher apoptotic levels than the control cells (Figure 23B). 
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 p ˃ 0.05 
Figure 23 – Quantification of PC-3 apoptotic cells. (A) Images of apoptosis from PC-3 derived cells 
at 72h in culture. (B) Quantification of apoptotic cells in PC-3 clones and shNeg during 48, 72 and 96h. 
Student t test was used to evaluate differences obtained. Bars represent standard deviation. 
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 As for MDA-PCa-2b derived cells, the results were quite similar. Qualitative analysis 
showed a slightly greater uptake of purple-red dye by MDA-PCa-2b-C1 and C2 cells when 
compared to the control (shNeg) (Figure 24A). This data was supported by results obtained 
at the quantitative level, where MDA-PCa-2b silenced clones demonstrated increased 
apoptotic rates when compared to control cells (Figure 24B). Nevertheless, the results were 
not statistically significant (p ˃ 0.05).  
 
 
 
 
 
 
 
Figure 24 – Quantification of MDA-PCa-2b apoptotic cells. (A) Images of apoptosis from MDA-
PCa-2b derived cells and shNeg control at 96h in culture. Use of hydrogen peroxide as a positive 
control. (D) Quantification of apoptotic rate in MDA-PCa-2b derived cells and the shNeg control during 
48, 72 and 96h in culture. Student t test was used to evaluate differences obtained. Bars represent 
standard deviation. 
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4.3. Colony formation 
 
We determined the ability of ETV4 to induce colonies formation in prostate cancer cells 
using an in vitro soft-agar assay. In contrast to PC-3 shNeg cells, ETV4-depleted cells 
showed a substantial decrease in colony formation after two weeks in culture, originating 
approximately 50-60% fewer colonies, which indicates a decrease in anchorage independent 
growth (Figure 25A). Pictures taken on the day when cells were seeded represent the 0h 
time-point and show the level of initial cellular aggregation, allowing a comparison to be 
made. Cell counting confirmed a significant decrease in the cell-cell aggregation level of    
PC-3-C1 and C2 clones when compared to the control (Figure 25B). 
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Figure 25 – Quantification of PC-3 cell-cell aggregation. (A) Images of aggregates formed. The 
first line shows cells at 0h time-point; the second line shows the colonies formed. (B) Quantification of 
colony formation index by cell counting. Student t test was used to evaluate differences obtained. Bars 
represent standard deviation. 
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In the MDA-PCa-2b cell line, ETV4-silenced clones also showed a decrease in the 
number of colonies when compared to shNeg control cells, after two weeks of incubation     
(Figure 26A). The results obtained by cell counting were also statistically significant             
(p ˂ 0.05) (Figure 26B), but the number of colonies formed in MDA-PCa-2b-C1 and C2 cells 
was not as inferior (about 20%) as it was in PC-3 derived cells. 
In conclusion, these findings suggest that ETV4 has a noticeable role during anchorage 
independent growth of prostate cells. 
 
 
 
 
Figure 26 – Quantification of MDA-PCa-2b cell-cell aggregation. (A) Images of aggregates formed 
in MDA-PCa-2b derived cells. The first line shows isolated cells at 0h time-point, the second line 
shows colonies formed. (B) Quantification of colony formation index in MDA-PCa-2b cell line by cell 
counting. Student t test was used to evaluate differences obtained. Bars represent standard deviation. 
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4.4. Cell invasion 
 
We conducted an in vitro invasion assay to evaluate the ability of PC-3 and            
MDA-PCa-2b derived cancer cells to invade through basement membrane matrix Matrigel. As 
the results in Figure 27A illustrate, PC-3 shNeg control cells were highly invasive, revealing 
an ability to break through the basement membrane, whereas PC-3-C1 and C2 cells hardly 
invaded. Even cell morphology was strikingly different, with the non-invading cells forming 
spheroid cultures and invading cells showing a spindle-shaped outgrowth (Figure 27A). The 
TPC-1 cell line was used as a positive control to confirm the assay’s reproducibility. 
Quantitative analysis was also obtained by measuring cells fluorescence, which were 
previously stained with calcein. The results showed a significant 40-50% decrease in PC-3-
C1 and C2 cell invasion when compared to the PC-3 shNeg control (Figure 27B).  
As for MDA-PCa-2b derived cells, the C1 and C2 clones did not cross the basement 
membrane at a significantly different rate when compared to the control cells (Figure 28A). 
Instead of depicting mesenchymal characteristics, the ETV4-depleted clones and respective 
control exhibited a spheroid cellular morphology, typical of non-invading cells (Figure 28A). 
At the quantitative level, there were no significant differences in cell invasion of MDA-PCa-2b-
C1 and C2 cells when compared to the MDA-PCa-2b control (Figure 28B). The high 
concentration of BME extract used (12mg/mL) could be avoiding cell’s ability to invade, 
therefore the assay was repeated using a less concentrated BME layer (10mg/mL). However, 
the same lack of invasiveness was observed (data not shown). In both situations the positive 
control – TPC-1 cell line – has managed to invade the basement membrane. 
In conclusion, the data obtained suggests that ETV4 expression is essential for the 
invasive phenotype of the PC-3 cells, but has no significant effect in promoting cell invasion in 
the MDA-PCa-2b cell line. 
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Figure 27 – Measurement of PC-3 cell invasion. (A) Images depicting which cells have invaded. The 
first line shows the PC-3 shNeg and TPC-1 cells that have traverse the basement membrane extract; 
the second line shows C1 and C2 cells with decreased cell invasion. (B) Quantification of cell invasion 
in the PC-3 derived cells. Student t test was used to evaluate differences obtained. Bars represent 
standard deviation. 
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Figure 28 – Measurement of MDA-PCa-2b cell invasion. (A) Images of the detection area showing 
which cells have invaded. The first line displays the MDA-PCa-2b shNeg and TPC-1 cells and the 
second line shows the MDA-PCa-2b-C1 and C2 clones. (B) Quantification of cell invasion in MDA-
PCa-2b derived cells. Student t test was used to evaluate differences obtained. Bars represent 
standard deviation. 
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4.5. Gene expression profile 
 
In an effort to gain a better understanding of the effect of ETV4 in the cellular models, 
we generated a comprehensive gene expression profile for PC-3 and MDA-PCa-2b cells 
associated with ETV4 silencing. A list of two genes up-regulated with ETV4 and six genes 
down-regulated with ETV4 (Table 7) was obtained following the described criteria. The 
Functional Gene Ontology (GO) term is shown for each gene. Although some have an 
unknown function, and the majority of the genes are not highly explored in the literature, they 
are generally described to be involved in proliferation and regulation of cell cycle.  
As shown in Table 7, the top gene of our list commonly altered in the two cell models 
was, as expected, ETV4, followed by the C1orf129 and PAK1IP1 genes. For the            
down-regulated targets, FTH1, KIAA1199, PLK2, SPTLC3, TLL1 and TMEM154 were the top 
most differentially expressed genes in the two cell lines (Table 7). 
 
 
Table 7 – Genes up-regulated and down-regulated by ETV4 in PC-3 and MDA-PCa-2b cells. 
 
 
 
Gene name 
 
 
GO Biological Process Term 
 
 
PC-3 
 
 
MDA-PCa-2b 
 
 
Genes up-regulated by ETV4 
 
ETS variant 4 (ETV4) 
 
Sequence-specific DNA binding 
transcription factor activity 3.37 2.58 
 
Chromosome 1 open reading 
frame 129 (C1orf129) 
 
 
Unknown 
1.70 1.52 
 
PAK1 interacting protein 1 
(PAK1IP1) 
 
Negative regulation of signaling 
transduction 1.84 2.62 
 
Genes down-regulated by ETV4 
 
Ferritin, heavy polypeptide 1 
(FTH1) 
 
 
Iron ion transport / intracellular 
sequestering of iron ion / immune 
response / negative regulation of cell 
proliferation / oxidation reduction 1,70 2,01 
 
(KIAA1199) 
 
 
Unknown 2,04 1,54 
 
Polo-like kinase 2 (PLK2) 
 
Mitotic cell cycle / protein amino acid 
phosphorylation / positive regulation of 
I-kappaB kinase/ NF-kappaB cascade 1,63 1,56 
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Serine palmitoyltransferase, 
long chain base subunit 3 
(SPTLC3) 
 
 
biosynthetic process / sphingolipid 
biosynthetic process 
2,01 1,58 
 
Tolloid-like protein 1 (TLL1) 
 
 
Skeletal system development / 
proteolysis / multicellular organismal 
development / cell differentiation 1,99 1,99 
 
Transmembrane protein 154 
(TMEM154) 
 
 
Unknown 
1,83 2,23 
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DISCUSSION 
 
Members of the ETS family of transcription factors, which comprises more than 27 
genes, are usually defined by a highly conserved ETS domain capable of recognizing DNA 
sequences containing a G-G-A trinucleotide (Karim et al. 1990; Sharrocks 2001), and seem 
to play important roles in processes such as proliferation, migration, invasion, angiogenesis 
and apoptosis carried out during the pathogenesis of several cancers (Sementchenko and 
Watson 2000; Oikawa and Yamada 2003; Seth and Watson 2005). This functional diversity of 
ETS proteins suggests that target site selection is critical for biological regulation (Szymczyna 
and Arrowsmith 2000; Hollenhorst et al. 2004). 
Mounting evidence associates ETS transcription factors with certain tumor 
chromosomal rearrangements, which generally result in the formation of gene fusions, 
typically found in the majority of prostate cancers (Mitelman 2000; Kumar-Sinha et al. 2008; 
Morris et al. 2008; Tomlins et al. 2009; Mani et al. 2010). This discovery led to a greater 
understanding of prostatic carcinogenesis within the last decade, providing new concepts for 
the identification of diagnostic markers and development of new targeted therapies. To date, 
ERG is one of the most affected ETS genes, frequently fused with the androgen-regulated 
TMPRSS2 gene (Tomlins et al. 2005; Perner et al. 2006; Soller et al. 2006; Clark et al. 2007; 
Liu et al. 2007), followed by ETV1 (Tomlins et al. 2007b; Attard et al. 2008b; Hermans et al. 
2008b), ETV4 (Tomlins et al. 2006), ETV5 (Helgeson et al. 2008) and FLI1 (Paulo et al. 
2012a), often with promoter fusion partners other than TMPRSS2. 
Since the biochemical mechanisms by which elevated ETS contribute to the 
development and/or progression of prostate cancer need further clarification, several studies 
in cell lines have now implicated ERG, ETV1 and ETV5 as regulators of invasive growth – a 
key aspect of the tumor phenotype (Tomlins et al. 2007b; Helgeson et al. 2008; Sun et al. 
2008; Tomlins et al. 2008; Watson et al. 2010). Moreover, a recent work has shown that high 
expression levels of ETV4 are necessary for robust anchorage-independent growth 
(Hollenhorst et al. 2011b). Nevertheless, information about the ETS biological roles and their 
downstream target genes remains insufficient, and a careful comparison of the function of 
individual ETS family members in cell lines could address questions of redundant and specific 
carcinogenic properties. 
In line with this, we investigated throughout this study whether ETV4 overexpression 
shows a similar mechanistic and functional involvement in tumor biology of cell lines with and 
without known genomic rearrangements in other ETS genes. 
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We showed for the first time the different ETS expression patterns in a variety of cell 
lines representing diverse molecular subtypes of prostate carcinogenesis. We confirmed 
previous findings showing ERG and ETV1 overexpression in VCaP and LNCaP cells 
respectively (Tomlins et al. 2005; Cai et al. 2007; Tomlins et al. 2007b; Tomlins et al. 2008), 
as well as ETV4 overexpression in the PC-3 prostate cancer cell line (Hollenhorst et al. 2004; 
Hollenhorst et al. 2011b). Additionally, we found a high co-overexpression of ETV1 and ETV4 
levels in MDA-PCa-2b cells, along with a moderate expression of ETV1 in PC-3 cell line. The 
PNT2 benign cell line used in this panel showed small baseline levels for these two ETS. 
The co-overexpression of two ETS in the same cell line contradicts the original 
hypothesis of mutual exclusivity within an individual tumor (Tomlins et al. 2005; Svensson et 
al. 2011). However, there could be two distinct populations in the MDA-PCa-2b cellular model 
that express each one of the ETS independently, reinforcing the idea reported by Clark et al. 
and our group that more than one ETS rearrangement can exist in a prostate gland (Clark et 
al. 2008b; Paulo et al. 2012a). Based on these findings, we evaluated the presence of any 
chromosomal rearrangement that might have occurred within the ETV4 gene in PC-3 and 
MDA-PCa-2b cells. Although our results did not confirm a genetic rearrangement consistent 
with a fusion gene involving ETV4, and contrarily to what was reported by Hollenhorst et al. 
(2011), we were able to identify a structural genomic alteration in the PC-3 cell line that 
consisted in the presence of the 5’ region of the ETV4 gene located in two similar aberrant 
chromosomes, in addition to three chromosomes 17 with no rearrangements. Since the two 
additional isolated red signals in the PC-3 cell line represent 5’-ETV4 and not 3’-ETV4, it is at 
present unclear how it is related to the observed ETV4 overexpression. As for the MDA-PCa-
2b cells, there was no rearrangement mediating the aberrant overexpression of ETV4, 
whereas previous results have demonstrated the presence of a balanced t(7;14)(p21;q21) 
translocation corresponding to the locations of the ETV1 and MIPOL1 loci (Bokhoven et al. 
2003; Tomlins et al. 2007b). This rearrangement, also confirmed by us through FISH 
analysis, justifies ETV1 outlier overexpression in the MDA-Pca-2b cell line. According to the 
literature, there are two other prostate carcinoma cell lines that harbor well characterized ETS 
fusions, namely VCaP and LNCaP cells. The genetic rearrangements in each of these in vitro 
models have been shown to be responsible for overexpressing the respective ETS family 
members – ERG and ETV1 (Tomlins et al. 2005; Perner et al. 2006; Tomlins et al. 2007b). 
The mechanism of ETV4 overexpression in both PC-3 and MDA-PCa-2b cell lines remains 
unclear and may be mediated by mechanisms other than ETV4 genomic rearrangements. 
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The present study has demonstrated a significant increase of ETV1 expression in PC-3 
transfectant cells after ETV4 knockdown, whereas MDA-PCa-2b derived cells did not show 
such difference. It is thus reasonable to hypothesize that the PC-3 prostate cancer cell line 
probably has a compensatory mechanism capable of favoring initially moderate ETV1 
expression in the absence of ETV4, presumably reflecting an at least partial redundancy to 
maintain the neoplasic phenotype. As for MDA-PCa-2b cells, the absence of a further 
increase of ETV1 mRNA levels after ETV4 depletion suggests that the compensatory effect 
does not bring any adaptive advantage to the cell, maybe because the ETV1 overexpression 
in this cell line is extremely high. These expression data and the genomic findings described 
above indicate that the co-overexpression of the two ETS genes occurs in the same cells and 
are not the result of genetic heterogeneity.  
At the time of writing of this thesis, an article addressed the oncogenic role of ETV4 in 
prostate cells and reported some of the findings we here present concerning PC-3 (Pellecchia 
et al. 2012), but it did not include comparison with the MDA-PCa-2b cell line.                    
They have selected the prostate cancer cell lines PC-3 and DU-145 based on ETV4 protein 
expression levels to induce its silencing via a doxycycline system, and a nonmalignant human 
prostate cancer cell line – RWPE – to study the effect of induced ETV4 overexpression. 
However, the DU-145 cell line showed ETV4 transcript levels more similar to RWPE cells 
than to PC-3. Thus, we believe that the MDA-PCa-2b cell line has advantage over DU-145, 
since it expresses almost the same mRNA levels of ETV4 as PC-3 cells and allows us to 
evaluate the role of co-overexpression of two different ETS genes in prostate carcinogenesis, 
with or without known ETS genomic rearrangements. 
Functional evaluation revealed no effect of ETV4 silencing on the proliferative 
phenotype of PC-3 and MDA-PCa-2b derived prostate cancer cells. The observed response 
was consistent with other study that has previously reported no alteration in the rate of growth 
of the PC-3 cell line on a solid surface after knockdown of ETV4 (Hollenhorst et al. 2011b). 
Notwithstanding, it contradicts the work of Pellecchia et al. (2012), who showed a reduction in 
PC-3 and DU-145 cell number after ETV4 shRNA in a H3 thymidine uptake assay. 
Conversely, the nonmalignant RWPE cell line has demonstrated an inverse effect, revealing 
a higher cell growth rate after ETV4 overexpression (Pellecchia et al. 2012). These 
differences may be explained by the use of distinct methodological approaches. A couple of 
studies have also shown that ETV4 can positively regulate cell proliferation in other tumor 
models, such as colon and oesophageal carcinomas (Moss et al. 2006; Keld et al. 2010). 
Another observation was that apoptosis was not significantly increased in PC-3 and MDA-
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PCa-2b clones when compared to the controls, though a tendency for higher apoptotic levels 
in the silenced cells was seen. Only two studies evaluated the role of ETV4 in the apoptotic 
rate. The first one did not observe any significant variation of the percentage of apoptotic 
prostate cancer cells by flow cytometry, either after ETV4 silencing or overexpression 
(Pellecchia et al. 2012), being in aggrement with our results. The second work verified that 
ETV4 overexpression enhanced apoptosis and expression of the pro-apoptotic protein Bax 
via DNA-binding domain in the chemotherapeutically treated hepatocellular carcinoma Huh-7 
and Hep3B cell lines (Liu et al. 2008). Taken together, since most ETS factors were initially 
characterized as both transcription activators or repressors involved in a dynamic regulatory 
network, it is likely that the ETV4 transcription factor has a more context-dependent role than 
a tissue-specific functional impact, which could explain the differences observed in different 
cell models. 
The neoplastic phenotype is complex, resulting from a series of genetic and epigenetic 
mutations that cause deregulation of cell fate and cell transformation. Since anchorage-
independent growth of cancer cells is a property believed to be an in vitro parameter 
indicative of malignancy, particularly with respect to metastatic potential, we sought to 
measure the effects of ETV4 silencing on colony formation in soft agar. The knockdown 
strongly impaired the ability of PC-3 and MDA-PCa-2b derived cells to grow in an anchorage-
independent way, decreasing the number of colonies formed. Others have also confirmed this 
effect in PC-3 (Hollenhorst et al. 2011b; Pellecchia et al. 2012), suggesting that high ETV4 
expression levels are necessary for robust anchorage-independent growth. Surprisingly, loss 
of this property was not observed after depletion of ETV1 and ERG in other prostate cancer 
cell models (Tomlins et al. 2007b; Tomlins et al. 2008), which might be due to the fact that 
downregulation of these ETS is not sufficient to revert the cell’s ability to form colonies in a 
tumor context. In contrast, functional analyses have confirmed that de novo overexpression of 
full-length ETV1 and ETV4 in PNT2 and RWPE benign prostate cell lines, respectively, 
induces an anchorage-independent growth phenotype (Hermans et al. 2008b; Pellecchia et 
al. 2012). Nevertheless, data regarding the RWPE cell line are still questionable, since 
another study refutes these results (Hollenhorst et al. 2011b). It will be interesting to explore 
in more detail the MDA-PCa-2b cell line model in order to evaluate the relative role of             
co-overexpression of ETV1 and ETV4. Results obtained in other tumor types seem to support 
the role of ETV4 in neoplasic transformation, namely in breast cancer, where ETV4-targeting 
siRNA repression resulted in anchorage-independent inhibition of cell growth (Firlej et al. 
2008; Clementz et al. 2011). 
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Another important feature of malignancy is invasion, which is defined by the ability to 
grow beyond the confines of the original location and constitutes the first step of metastasis 
(Behrens 1993). ETV4 expression has been associated with metastasis and with the 
activation of cancer-related genes relevant to invasiveness (Kaya et al. 1996; Launoit et al. 
2000; Discenza et al. 2004; Jiang et al. 2007). In the current work, PC-3 control cells clearly 
showed a significant capacity to invade through basement membrane extract when compared 
to the silenced clones, which revealed a decrease by ~ 50%. The PC-3 shNeg invading cells 
underwent spindle-shaped morphological changes, associated with the acquisition of a 
mesenchymal phenotype, while PC-3 shETV4 cells kept their epithelial phenotype. We thus 
confirmed that reduced ETV4 levels, achieved by knockdown, decrease cells invasiveness. 
Another study has confirmed an identical outcome in PC-3 and RWPE cell lines (Pellecchia et 
al. 2012), revealing consistency with the invasive growth promoting effect of ETV1 and ERG 
overexpression in other cancer lines (Cai et al. 2007; Rahim et al. 2011).  As for the MDA-
PCa-2b cell line, described as being noninvasive (Hara et al. 2008b), no differences were 
found between the shRNA clones and control cells, which may unveil the inability of ETV4 
and ETV1 overexpression to promote an invasive phenotype in this cellular model. This 
invasive phenomena, often with the involvement of matrix metalloproteinases (MMP) in loss 
of cell-cell adhesion and tumor cell-extracellular matrix interactions, has been shown to occur 
in lung, breast, colon, ovarian, esophagus and stomach cellular models as well (Hiroumi et al. 
2001; Shepherd et al. 2001; Lynch et al. 2004; Moss et al. 2006; Dahl et al. 2007; Firlej et al. 
2008; Keld et al. 2010; Keld et al. 2011). In addition, ETV4 has also been implicated in 
cellular migration of prostate cancer cells (Hollenhorst et al. 2011b; Pellecchia et al. 2012) 
and tumor growth in xenograft models (Pellecchia et al. 2012). 
Finally, a microarray analysis was performed to characterize and compare gene 
expression profiles of the two cell lines (PC-3 and MDA-PCa-2b), more specifically to assess 
whole-transcriptome expression levels between the shNeg control and the two independent 
shETV4 clone populations. Assembling genes on the basis of their function allowed us to 
group differentially expressed genes up or down-regulated with ETV4 into distinct categories. 
Despite some of them being novel or unexplored, the majority is described to play a role in 
cell cycle or cell growth functions. Similar results have also been shown by other study 
(Hollenhorst et al. 2011b). Our list highlighted two and six up- and down-regulated genes, 
respectively, in the two cell lines with an at least 1.5-fold increase, namely C1orf129 and 
PAK1IP1, or decrease, particularly FTH1, KIAA1199, PLK2, SPTLC3, TLL1 and TMEM154. 
This study stands out from others because it uses a cross-sectional approach rather than a 
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single cell line, therefore the expression pattern alterations of these target genes can be 
firmly attributed to ETV4 and not to the genetic background of any of the prostate cancer 
cells. 
C1orf129 is an open reading frame encoding an uncharacterized protein with no 
apparent relevance in prostate carcinogenesis, whereas PAK1IP1 encodes a PAK1 
interacting protein 1 known to have a role in cell proliferation and cell cycle via the p53-
pathway (Yu et al. 2011), and has been described to negatively regulate the activity of PAK1 
(Xia et al. 2001). PAK1 is a p21-activated kinase 1 that has recently been shown to induce 
anchorage-independent colonies formation in breast cancer cells leading to a malignant 
transformation (Shrestha et al. 2012). Since the cellular and biochemical functions of 
PAK1IP1 are poorly understood, an interaction between these two genes could be explored 
in prostate cancer cells. Regarding the top six down-regulated genes, the H ferritin gene 
(FTH1) has been shown to be involved in different biological events, such as cell 
differentiation and pathologic states besides regulating intracellular iron homeostasis. In order 
to analyze differential profiles of candidate prostate tumor markers, a comparison of the 
expression levels of several cancer-related genes revealed that FTH1 was up-regulated in a 
set of prostate tumors when matched to normal prostate tissues (Grzmil et al. 2004). On the 
other hand, in vitro assays have demonstrated a decreased growth activity as well as a 
reduced invasiveness and cell adhesion capability of human metastatic melanoma cells after 
silencing of FTH1 (Di Sanzo et al. 2011). Recent evidence showed that this protein is also 
capable of inducing apoptosis through inhibition of the JNK signaling pathway and interaction 
with the death domain-associated protein Daxx (Liu et al. 2012). As for KIAA1199, it has been 
mostly implicated in gastric and colon cancer. In the former cell model, this uncharacterized 
gene was found to be highly expressed and associated with prognosis and lymph node 
metastasis in a multivariate analyses (Matsuzaki et al. 2009), while in the latter model 
KIAA1199, which was stably silenced in the colorectal adenocarcinoma SW480 cell line, not 
only affected the cell cycle and the Wnt-signaling pathway, but also reduced cellular 
proliferation (Birkenkamp-Demtroder et al. 2011). Regarding the PLK2 gene, it seems to be 
involved in normal cell division, whereas SPTLC3 encodes a serine palmitoyltransferase that 
catalyzes the de novo synthesis of sphingolipids. Furthermore, the TLL1 is a tolloid-like 
protein 1 and is suggested to play multiple roles in the development of mammalian heart, 
while the TMEM154 gene has an unknown function. Still, there are no studies associating any 
of these genes with prostate cancer. 
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With the aim to evaluate whether the two most common ETS involved in 
rearrangements in PCa – ERG and ETV1 – regulate specific or shared downstream targets, a 
differential exon-level expression analysis on a series of prostatectomy samples was recently 
reported by our group (Paulo et al. 2012b). Since ERG, ETV1 and ETV4 belong to the same 
family of transcription factors, and the latter two to the same subfamily, we have compared 
the list of genes associated with tumors harboring ERG and/or ETV1 rearrangements with the 
ETV4 target genes we uncovered in this study. Although no ETS shared target gene was 
found in any of the lists generated, this does not indicate a less relevant role of these ETV4 
downstream targets in prostate carcinogenesis. In fact, even ERG and ETV1 show distinct 
tumor-associated target genes, which suggests that there are different expression patterns 
and individual properties unique of each ETS or that they are dependent on cellular 
environment. Though it is tempting to assume that all ETS family members function in a 
similar manner, it is becoming clear that this is not the case. 
In conclusion, this study provided additional information on the role of ETV4 in prostate 
carcinogenesis and unraveled novel target genes mediating this prostate cancer molecular 
subtype. The ability to dissect these molecular signatures, so as to reveal discrete aspects of 
the biology underlying the oncogenic phenotype, will be critical to understand the various 
mechanisms of the disease. 
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CONCLUSIONS AND FUTURE PERSPECTIVES 
 
Herein we provided evidence for a relevant role in oncogenesis for one member of the 
ETS family of transcription factors – ETV4. The results from this study demonstrated that 
ETV4 is an ETS transcription factor with critical activities in cell transformation and 
aggressive phenotype. We conclude that ETV4 knockdown is responsible for the 
downregulation of anchorage-independent growth in the PC-3 and MDA-PCa-2b derived cells 
and for decreasing the ability of PC-3 cells to invade, strongly implicating this oncoprotein in 
prostate tumorigenesis. Our microarray analysis has also shown a signature that exhibits 
characteristics of deregulated target genes mainly involved in cell proliferation and cell cycle 
function. Nevertheless, new questions and challenges remain to be addressed, providing us 
with new research opportunities. Some of them are highlighted below: 
 
 Despite the conserved DNA binding domain, ETS transcription factors are known 
to function strictly as activators or repressors, while others have dual roles 
depending on the state of the cell. Since the MDA-PCa-2b cell line shows ETV4 
and ETV1 co-overexpression in the same cellular context, it will be interesting to 
identify their specific and cooperative contribution for the malignant phenotype of 
this cell line model. 
 
 ETS proteins appear to play a critical, and possibly redundant, role in 
transformation. It is possible that ETV4 overexpression, whether driven by a 
chromosomal rearrangement or otherwise, may function as a powerful oncogene. 
But, given the enhanced effects produced by androgens, would the phenotypic 
effects of ETV4 silencing be different under androgen stimulation? 
 
 More than 50% of the prostate carcinomas we previously analyzed presented 
chromosomal rearrangements of at least one ETS gene, resulting in 
overexpression of the respective ETS transcription factor. A comparison of whole-
genome expression profiles between clinical prostate tumor samples positive for 
ETV1 or ETV4 fusions and our cell lines will pinpoint the most relevant candidate 
genes, which then could be subjected to further functional validation. 
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